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Pancreatic ductal adenocarcinoma (PDAC) represents the fourth most
common cause of cancer-associated death in the United States. Little progress has
been made in understanding how proteotoxic stress affects rapidly proliferating
pancreatic tumor cells. Endoplasmic reticulum (ER) stress occurs when protein
homeostasis in the ER lumen is perturbed. ER stress activates the unfolded protein
response (UPR) to reduce the protein load in the ER. Under conditions of moderate
ER stress, the UPR promotes cell cycle arrest which allows time for successful
protein load reduction and enables cell survival. However, under conditions of high
levels of ER stress the UPR induces cellular apoptosis. In this dissertation, I
investigated the role of endoplasmic reticulum (ER) stress and its effects on the cell
cycle in pancreatic cancer cells.
Activation of the unfolded protein response after ER stress induction was
determined by comparing expression of key UPR mediators in non-tumorigenic
pancreatic ductal cells to pancreatic cancer cells. Two arms of the UPR were
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assessed: eIF2α/ATF4/CHOP and IRE1α/XBP1s. Pancreatic cancer cells exhibited
altered UPR activation characterized by a delay in both phosphorylation of eIF2α
and induction of spliced XBP1. Further evaluation of the UPR-mediated effects on
cell cycle progression revealed that pancreatic cancer cells showed a compromised
ability to inhibit G1 to S phase progression after ER stress. This reduced ability to
arrest proliferation was found to be due to an impaired ability to downregulate cyclin
D1, a key gatekeeper of the G1/S checkpoint. Abrogation of cyclin D1 repression
was mediated through a slow induction of phosphorylation of eIF2α, a critical
mediator of translational attenuation in response to ER stress.
In conclusion, pancreatic cancer cells demonstrate a globally compromised
ability to regulate the unfolded protein response. This deficiency results in reduced
cyclin D1 repression through an eIF2α-mediated mechanism. These findings
indicate that pancreatic cancer cells have increased tolerance for elevated ER
stress compared to normal cells, and this tolerance results in continued tumor cell
proliferation under proteotoxic conditions.
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CHAPTER ONE: INTRODUCTION
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INTRODUCTION TO THE PANCREAS
The pancreas is a highly complicated secretory organ that serves as a critical
component of the gastrointestinal system. Its main role in the digestive tract is to
secrete digestive enzymes that promote breakdown of ingested food. Knowledge of
the anatomy of the pancreas and its location relative to surrounding organ
structures is important to the understanding of pancreatic physiology and its role in
the digestive system.

Anatomy of the Pancreas
The pancreas is located in the retroperitoneum of the abdomen, just posterior
to the stomach. In the adult, the pancreas is 12-20 cm in length and weighs
between 70-110 grams. It is an obliquely positioned organ that extends from the Cloop of the duodenum to the splenic hilum. The pancreas is composed of mainly
five segments: the head, uncinate process, body, neck, and tail. Each of these
segments is in close proximity to important organ and vascular structures. The
pancreatic head is surrounded by the second and third curvature of the duodenum.
Anteriorly, the pylorus of the stomach, the first part of the duodenum, and the
transverse colon lie adjacent to the pancreatic head. Posteriorly, the pancreatic
head lies in close proximity to the right kidney and its renal vessels, the inferior vena
cava, the right gonadal vein, and the right crus of the diaphragm. The uncinate
process is variably present in the population. It projects inferiorly from the
pancreatic head. Important surrounding structures include the aorta and inferior
vena cava located posteriorly. The superior mesenteric vessels are located
2

superiorly to the uncinate process and emerge from below the neck of the
pancreas.
Each of these regions of the pancreas has a distinct mechanism of
development during embryologic growth that led to the subsequent arrangement of
the pancreatic ductal system. During embryologic development of the foregut, the
pancreas initially begins from the fusion of both the ventral and dorsal buds. The
hepatic diverticulum gives rise to the ventral bud while the dorsal bud arises from
the duodenum. The pancreatic segments are formed with rotation of the ventral
bud around the duodenum and fusion with the dorsal bud. Both the inferior portion
of the pancreatic head and uncinate process are derived from the ventral bud while
the pancreatic body and tail originate from the dorsal bud. When these two buds
fuse, the pancreatic ductal system is formed. Many normal anatomic variations
exist, but the pancreatic ductal system is typically formed by the fusion of the ducts
in the two buds. The pancreatic ductal system is most commonly composed of
primarily the main pancreatic duct and the lesser pancreatic duct. The main
pancreatic duct arises from fusion of the ducts in the ventral and dorsal buds into
the Duct of Wirsung at the pancreatic head. It is formed from the many
anastomosing ductules that drain the lobules of the pancreas. It combines with the
common bile duct to form a shared segment, called the ampulla of Vater, which
drains at the duodenal papilla into the duodenum. The lesser pancreatic duct arises
from persistence of the duct from the dorsal bud as the Duct of Santorini and
usually joins the main pancreatic duct. This accessory duct can drain into the
duodenum at the minor papilla or in about 30% of cases, will end blindly without
3

draining (1). In about 10% of the population, fusion of the embryonic dorsal and
ventral buds fails to occur and forms a normal variant called pancreas divisum (2).
In this variant, the Duct of Santorini does not communicate with the Duct of Wirsung
and the Duct of Santorini is mostly responsible for draining pancreatic secretions
rather than the Duct of Wirsung.

Pancreatic Histology
The pancreas is a nodular gland that is composed of lobules loosely
connected by connective tissue septa. The majority of the pancreas (85%) is
comprised of exocrine cells while only 2% are endocrine (1). The remainder of the
pancreas consists of extracellular matrix, blood vessels, and excretory ducts of the
pancreas. The pancreas is composed of mainly three cell types: acinar cells,
intercalated duct cells, and centroacinar cells. Acinar cells are arranged into a
functional unit, called an acinus, with a central lumen. Centroacinar cells lie near
the center of the acinus. The acinus then forms small intercalated ducts, which are
lined by the intercalated duct cells. Multiple small intercalated ducts converge to
form an interlobular duct. Each acinar cell contains zymogen granules that release
digestive enzymes into the acinar lumen as pancreatic fluid. The zymogen granules
contain 12-15 specific digestive enzymes, including amylase, proteases, and
lipases, that aid in the processing of carbohydrates, protein, and fat (2). The
composition of pancreatic enzymes in the pancreatic fluid is adjusted according to
content of digested food. The centroacinar and intercalated duct cells contribute
water, bicarbonate, and other electrolytes as the pancreatic juice flows from the
4

acini to the interlobular ducts to the main pancreatic duct before finally secretion into
the duodenum. The resulting pancreatic juice is colorless, alkaline, and isosmotic.
Each day, the pancreas secretes about 500 to 800 ml in order to process dietary
intake.
The endocrine pancreas is composed of clusters of cells into structures
called the islets of Langerhans. Each islet contains cells of five major types: alpha
cells, β-cells, delta cells, epsilon cells, and PP cells. In contrast to the acinar cell
which is responsible for the secretion of multiple enzymes from a single cell, each
cell of the endocrine pancreas is mainly responsible for the secretion of one
hormone. Alpha cells secrete glucagon, β-cells secrete insulin, delta cells secrete
somatostatin, epsilon cells secrete ghrelin, and PP cells secrete pancreatic
polypeptide. Each of these hormones is involved in the regulation of glucose or
gastrointestinal function after a dietary challenge. Islet cell control is complicated
through the interplay of multiple inputs from hormonal feedback loops, neural
signals, and blood flow. Perfusion of the acinar cells comes from venous blood flow
draining from the islets, thus allowing the endocrine pancreas to influence the
secretions of the exocrine pancreas.

5

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Epidemiology
Pancreatic adenocarcinoma (PDAC) is a malignant tumor of the exocrine
pancreas. This type of neoplasm represents 85% of all neoplasms that occur in the
pancreas. Pancreatic cancer ranks as the fourth most common cause of cancerassociated deaths (3). While this malignancy only represents the tenth most
common malignancy, the diagnosis of pancreatic adenocarcinoma carries the worst
prognosis of all malignancies. An estimated 43,000 new cases of pancreatic cancer
will be diagnosed with an estimated 36,800 deaths in 2010 (4). The rate of mortality
closely follows the incidence rate with an abysmal 5-year survival rate of nearly 6%
(4, 5).
Risk of developing PDAC is considered multifactorial from a combination of
genetic and environmental factors. The overall lifetime risk of any individual is 1 in
71 (5). The most closely associated risk factor is increasing age. More than 68% of
PDAC occur in individuals older than 65 years of age with a median age of 72 years
(5). Incidence also predominates slightly in males over females (1.3:1) and is more
common in blacks compared to other races (16.7 per 100,000 black men compared
to 13.3 per 100,000 men of all races) (5). While several environmental risk factors
have been implicated, the most consistently demonstrated preventable risk factor
for PDAC is cigarette smoking with a 2.5 to 3.6 times the risk of a non-smoker (6).
Other risk factors that have been identified include chronic pancreatitis and
diabetes. Chronic cirrhosis, obesity, high fat or high cholesterol diets have been
associated less conclusively with PDAC (7) Ref 9 in Hidalgo NEJM 2009).
6

Clinical Presentation, Diagnosis, and Staging of PDAC
A key factor in the poor prognosis of PDAC can be attributed to the late
presentation and vague symptoms of the disease. The initial presentation of
pancreatic cancer depends on the location of the tumor. Most pancreatic
adenocarcinoma tumors arise in the pancreatic head and can result in obstructive
cholestasis and jaundice. Common presenting symptoms include nausea, anorexia,
vague abdominal discomfort, or deep dull upper abdominal pain that is poorly
localized. Obstruction of the pancreatic duct by the mass may result in acute
pancreatitis. In patients with newly diagnosed diabetes mellitus, pancreatic cancer
should also be ruled out. Unfortunately in most cases, by the time symptoms
become manifest, the cancer has already reached a level of progression that
surgical resection is no longer an option.
Once a physician suspects a possible pancreatic tumor, the standard of care
for the initial diagnosis and staging of PDAC is multiphase, multidetector helical
computed tomography (CT) with intravenous contrast injection using a specific highresolution protocol for the pancreas. This method of detection has been shown to
have an accuracy of 80-90% in predicting surgical resectability (8). Positronemission tomography has a supportive role in clarifying equivocal CT results.
Additional studies, such as endoscopic retrograde ultrasonography (ERCP), can be
used to obtain tissue samples for diagnosis and therapeutic stent placement for
duct obstruction for tumors located in the pancreatic head. For patients with signs
of advanced disease, such as weight loss, or in patients with large tumors or tumors
of the body or tail of the pancreas, an exploratory laparotomy may be indicated to
7

determine level of metastases and vascular involvement (9). While many serum
biomarkers have been investigated, the only currently clinically useful biomarker is
CA 19-9 and can be used to monitor treatment and early detection of recurrence of
pancreatic cancer (10-13). CA 19-9 is limited, however, since its utility has only
been demonstrated in already diagnosed pancreatic cancer and cannot be used as
a screening tool to detect previously undiagnosed pancreatic cancer.

Treatment of PDAC
Upon diagnosis of pancreatic adenocarcinoma, clinical management is
determined by the 3 factors: tumor burden, invasion into local tissues, and
metastasis to other sites. The extent of progression is determined at presentation
through a staging process. The current gold standard for pre-operative tumor
staging is through helical computed tomography (CT) to determine whether patients
have surgically resectable disease. Staging of pancreatic adenocarcinoma is based
on the American Joint Committee on Cancer classification system and is based on
tumor grade, nodal status, and metastatic involvement (14). Tumor resectability as
defined by the National Comprehensive Cancer Network (NCCN) Pancreatic
Adenocarcinoma Panel is determined by the absence of distant metastases,
absence of tumor thrombus and abutment or structural impingement on surrounding
major vessels of the superior mesenteric vein and portal vein (15). The tumor must
also show lack of involvement with the superior mesenteric artery, hepatic artery,
and celiac axis as evidenced by clear fat planes around the structures. Only about
20% of patients present with potentially resectable disease at presentation (16).
8

Recent studies indicate a 5-year survival rate of 20% for surgical resection alone for
pancreatic cancer with extension of the median survival time to 11-20 months (1721). The European Study Group for Pancreatic Cancer Trial 1 (ESPAC-1) and
Charité Onkologie 1 trial demonstrated that chemotherapy, either 5-fluorouracil (5FU) or gemcitabine improved overall survival after surgical resection (20, 22, 23).
Just recently, the ESPAC-3 trial demonstrated that gemcitabine was shown to be no
more beneficial over 5-FU in completely resected pancreatic cancer to improve
overall survival (24). Neoadjuvant therapy, or chemotherapy applied preoperatively, has been shown to have equal benefit compared to adjuvant
chemotherapy with an improved rate of local failures and decreased positive
resection margins (25).
In 80% of cases, patients present with unresectable pancreatic cancer have
disease that is either locally advanced or metastatic. Patients with metastatic
disease are treated with systemic therapy for palliation of symptoms rather as an
attempt at curative treatment. Currently, first-line therapy for locally advanced
disease includes systemic therapy with gemcitabine or a gemcitabine-based
combination therapy (26). Gemcitabine treatment alone was shown to provide a
clinical benefit response in 23.8% of patients as well as a small extension in overall
patient survival compared to 5-fluorouracil chemotherapy (27). Gemcitabine was
shown to provide a modest improvement in survival to 5.65 months in comparison
to 4.41 months with 5-fluorouracil (27). The only targeted therapeutic that shown to
improve survival over gemcitabine alone was erlotinib, an epidermal growth factor
inhibitor. Erlotinib provided a small but significant survival advantage of 6.24
9

months compared to 5.91 months for gemcitabine alone (28). The clinical
significance of such a small survival extension is still being debated. Gemcitabine
treatment in combination with a number of novel targeted therapies, including other
agents aimed at the EGF receptor, have failed to provide benefit over gemcitabine
alone in Phase III clinical trials (29-31). The combination of radiation with
chemotherapy has yet to demonstrate convincing results of a survival advantage
over chemotherapy (32).

Molecular Biology of Pancreatic Adenocarcinoma
Genetic predisposition is also a known component of development of PDAC.
However, only about 5-10% of patients with PDAC have a family history of the
disease (33). Strong evidence exists that the accumulation of both germline and
somatic gene mutations leads to PDAC. The gradual accumulation of these gene
mutations is believed to result in a sequential progression of normal pancreas to
various stages of pre-malignant lesions, called pancreatic intraepithelial neoplasias
(PanIns), to pancreatic adenocarcinoma. In a global genomic analysis of 24
pancreatic tumors, an average of 63 “likely relevant” genetic abnormalities in each
tumor were identified (34). Each tumor possessed its own variation of genetic
aberrations affecting signaling pathways that was unique from other tumors in the
study. This heterogeneity of accumulated mutations points to the inherent
difficulties in treating PDAC as a homogenous entity.
Four key genes have been identified as critical players in the carcinogenesis
of pancreatic adenocarcinoma: KRAS, CDKN2A, TP53, and SMAD4/DPC4.
10

Presence of at least one of these gene mutations has been demonstrated in nearly
all pancreatic cancers (35). Activating mutations in the KRAS oncogene has been
identified in 90% of pancreatic adenocarcinomas (36). KRAS mutation, however,
has demonstrated poor sensitivity (50%) owing to the presence of Ras pathway
activation even when negative for KRAS mutation and does not accurately predict
prognosis (37). KRAS has been demonstrated to be important to the initiation of
carcinogenesis of pancreatic cancer (38). Mutation of this oncogene results in a
constitutively active isoform of the Ras protein with consequent abnormal activation
of proliferative and pro-survival signals. Accrual of additional genetic alterations,
such as mutation or loss of CDKN2A or TP53, has been shown to be necessary to
initiate carcinogenesis into PDAC. Mutations of CDKN2A have been demonstrated
in 95% of PDACs. This mutation inactivates the p16 protein, a key regulator of the
G1-S cell cycle transition, with a subsequent increase in proliferation. In 50-75% of
cells, TP53 has been shown to be mutated. Mutation of this gene results in loss of
control over DNA damage checkpoints and apoptosis with a resultant genomic
instability that further promotes malignant transformation. A mutation in
SMAD4/DPC4 mutation has been identified in about 50% of PDAC tumors and
interferes with normal functioning of transforming growth factor β receptor (TGFβ).
Mutation of SMAD4 has been associated with a worse prognosis in surgically
resected pancreatic cancer (39).

11

ENDOPLASMIC RETICULUM STRESS AND THE UNFOLDED PROTEIN
RESPONSE
Overview of ER Stress
Perturbations in the homeostasis of the cellular microenvironment may lead
to changes in the organelle processing functions of the endoplasmic reticulum. The
endoplasmic reticulum (ER) is a cellular organelle composed of a complex network
of interconnecting tubules that is responsible for crucial control over protein
biosynthesis, folding, quality control, and post-translational modifications in the
secretory pathway. The ER is a necessary organelle for sequestration of
incompletely folded and immature proteins requiring further modifications which
would otherwise be unsuitable in the cytosolic environment.
Processes which challenge the ER’s ability to maintain homeostasis result in
a condition termed endoplasmic reticulum stress. These challenges interfere with
ER protein folding function and cause an increase in misfolded and excess protein
load in the ER. The accumulated protein load induces proteotoxic stress in the ER.
ER stress signals for activation of the unfolded protein response (UPR). The UPR
coordinates an integrated stress signaling pathway that balances survival against
the damages created by excessive protein stress in the ER. This pathway’s role is
to re-establish protein homeostasis by reducing protein load within the ER. This
pro-survival response is achieved through a complex system that attenuates protein
translation, upregulates ER chaperone folding capacity, and increases degradation
of aberrant protein through a process called ER-associated degradation (ERAD). If
the protein load exceeds the UPR’s capacity to decrease the proteotoxic stress, the
12

UPR converts from a pro-survival to a pro-apoptotic role with activation of the
intrinsic apoptosis pathway.
The UPR is an integrated cellular response composed of the interplay among
three ER transmembrane receptors which act as “sensors” to detect accumulated
and misfolded proteins within the ER lumen. The three receptors that have been
identified are called pancreatic ER kinase (PKR)-like ER kinase (PERK), inositolrequiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). The
mechanism of “detection” through these receptors is mediated through interactions
with the ER molecular chaperone GRP78 (Binding Protein/Glucose-Regulated
Protein 78kDa), and is also known as BiP (Binding Protein). GRP78 is constitutively
bound to these ER receptors and maintains them in an inactive state. Currently, the
most accepted theory is that the UPR is activated when misfolded proteins in the
ER lumen compete with the UPR receptors for binding to GRP78 and cause its
dissociation from the UPR receptors (41). GRP78 release subsequently relieves
PERK, IRE1, and ATF6 of their inhibition. GRP78 thus exerts powerful control over
the general regulation of the UPR (40).

PERK-eIF2α-ATF4 activation
Activation of PERK occurs through autophosphorylation and dimerization.
PERK acts as a serine/threonine kinase with two known substrates: eukaryotic
initiation factor 2α (eIF2α) and nuclear-factor E2-related factor 2 (Nrf2). For the
purposes of this study, only eIF2α was studied. Upon ER stress induction, PERK
phosphorylates the eIF2α subunit on Ser51, effectively inactivating the eIF2 ternary
13

complex. Subsequent global cap-dependent translation is inhibited (discussed
further later). Paradoxically, not all protein synthesis is inhibited. A number of
genes are selectively transcribed under stress conditions via cap-independent
translation. In response to ER stress, one such selectively translated mRNA is
activating transcription 4 (ATF4). The untranslated region of the ATF4 mRNA
sequence contains three alternative untranslated open reading frames (uORFs)
which are specifically translated in response to certain stresses. When active eIF2
ternary complexes are abundant, the primary open reading frame is translated,
leading to a STOP codon and no protein is translated. When the availability of
active eIF2 ternary complexes is limited, such as when eIF2α is phosphorylated, the
alternative uORF is read and ATF4 is translated. General translational control by
eIF2α phosphorylation will be discussed in more detail later.

IRE1α-XBP1s activation
The cytosolic domain of IRE1α possesses intrinsic endoribonuclease
function which has only one known target: XBP1 precursor messenger RNA.
GRP78 release results in disinhibition of IRE1α, causing its activation through
dimerization and trans-autophosphorylation. Once activated, the endoribonuclease
site splices an intron of 26 nucleotides from the XBP1 precursor mRNA. Upon
splicing, a frameshift in the reading frame results in the translation of the spliced
XBP1 mRNA into a spliced XBP1 (XBP1s) protein that acts as potent transcription
factor for UPR gene expression (42, 43). XBP1s promotes transcription of genes
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that upregulate ER chaperone expression, ER biogenesis in secretory cells such as
the exocrine pancreas, and ER associated degradation (ERAD) (44-47).

ER Stress-Mediated Apoptosis
Under conditions of prolonged ER stress, cells undergo apoptosis induction.
The PERK pathway promotes selective translation of ATF4. ATF4 subsequently
induces CHOP (C/EBP homologous protein), which is also known as GADD153
(48). Although more closely studied in association with the PERK pathway, CHOP
can additionally be induced by the IRE1α and ATF6 pathways (49). CHOP
induction leads to derepression of protein synthesis via dephosphorylation of eIF2α
by GADD34. Subsequent protein synthesis is increased and cell death is induced
via continued accumulation of proteotoxic stress (50). CHOP has also been shown
to promote expression of a number of pro-apoptotic genes and downregulation of
anti-apoptotic genes, such as Bcl2 (51-53). Apoptosis via CHOP was demonstrated
to be elicited via an ER stress-specific mechanism. CHOP-deficient cells
demonstrated increased resistance to ER stress-mediated apoptosis (54). ER
stress-mediated apoptosis is believed to be conducted via the proapoptotic Bcl2
proteins.
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Figure 1. The unfolded protein response (UPR) pathway. The unfolded protein
response pathway is initially activated by accumulation of misfolded proteins in the
ER, resulting in release of GRP78 binding from the transmembrane receptors
PERK, ATF6, and IRE1. GRP78 dissociation results in activation of PERK, ATF6,
IRE1 cascades which promote inhibition of protein synthesis, upregulation of ER
chaperones, and protein degradation. Initial activation of the UPR results in cell
survival from decreased protein load and ER stress. Failure to reduce protein load
results in apoptosis (not depicted). Adapted with permission from Physiological
Reviews, Marciniak and Ron, 2006 (55). This is an unofficial adaptation of an
article in a publication of the American Physiological Society. The American
Physiological Society has not endorsed the content of this adaptation or translation,
or the context of its use.
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ER Stress and Cancer
Given the limited availability of a functional vascular supply in most
pancreatic adenocarcinomas, the tumor microenvironment of pancreatic tumors
would be expected to be deficient in important metabolites such as glucose,
oxygen, and amino acids (56). This tumor microenvironment would provide for
conditions predisposing tumors to an ER stress state. Tumor cells exhibit an
increased dependency on glucose due to their reliance on glycolysis rather
oxidative phosphorylation, otherwise known as the “Warburg effect” (57). Glucose
deprivation results in decreased ATP availability and decreased efficiency of ATPrequiring protein folding enzymes. Additionally, inflammatory factors have also
been implicated to be regulated by the UPR. The contribution of inflammation has
been of key importance in the pathogenesis of cancer, particularly in pancreatic
cancer. ER stress has been demonstrated to induce NFκB and may regulate it both
negatively and positively and in a phase dependent fashion. A number of studies
have established PERK and the UPR as an adaptive cellular mechanism to combat
the protein stress created by hypoxic and metabolic stresses (58-61). This
cytoprotective response is of particular importance in cancer since expression of
UPR factors has been correlated to increased proliferative capacity, tumor growth,
and metastasis (58, 61-63). Most recent evidence indicates that PERK may also
help ameliorate proteotoxic stress in tumor cells, thus promoting their survival (6264).
Particular attention has recently been paid to the UPR as new therapeutics
targeting PERK are under investigation (59, 65). Multiple drugs have demonstrated
17

ER stress activation that promotes apoptosis, including proteasomal inhibitors and
cisplatin (66-69). One barrier to chemoresistance in cancer with UPR targeting
agents is perhaps the difficulty in identifying a therapeutic index between the
cytoprotective versus apoptotic effects of ER stress induction. Although activation
of ER stress can cause apoptosis in cancer cells, an obvious difficulty is the dual
role that the UPR plays in mediating both apoptosis and survival. ER stress
activation promotes cytoprotective processes, such as protein folding through ER
chaperones like GRP78. GRP78 is frequently upregulated in cancers and has even
been shown to be displayed on the cell surface of tumor cells (70, 71). A number of
studies indicate that GRP78 plays a significant role in promoting tumorigenicity,
angiogenesis, and chemoresistance. Ironically, despite evidence mentioned
previously that the UPR is believed to play a mostly pro-tumorigenic role,
overexpression of GRP78 inhibits the UPR through suppression of the UPR
sensors. This dynamic that GRP78 and the UPR both promote tumorigenesis seem
at odds with current evidence that one represses activation of the other. Whether
this represents a difference in responses in various cell types or a modulation of ER
stress based on the stress applied is yet to be clarified.
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CYCLIN D1 REGULATION
In normal cells, D-type cyclins play a critical role in promoting cell cycle
progression through the G1 restriction point. Cyclin D1 expression is dependent on
cell cycle phase. Its expression rises early in G1 phase and declines rapidly upon
entry into the G1/S phase boundary. Cyclin D1 forms a complex with cyclindependent kinase-4 (CDK4) or cyclin dependent kinase-6 (CDK6) that
phosphorylates the retinoblastoma protein. Hyperphosphorylation of the
retinoblastoma molecule results in its release of E2F transcription factors, thus
allowing transcription of cell cycle genes promoting the G1 to S transition. Cyclin
D1 thus acts as a rate-limiting step for progression through the G1 phase.
As expected, overexpression of cyclin D1 leads to more rapid progression
through the G1 checkpoint and promotion of proliferation (72-74). These cyclins
promote cell proliferation by transmitting mitogenic stimuli to the cell cycle
pathways. Transcriptional regulation of cyclin D1 occurs through multiple inputs,
including the Ras/Raf/MAPK and nuclear factor kappa B (NFκB) pathways.
Ras/Raf/MAPK and NFκB pathways are two pathways known to contribute to the
pathogenesis of pancreatic cancer (75).
Most research seems to support the role of cyclin D1 as a pro-tumorigenic
factor in tumor cells. Cyclin D1 is known to be overexpressed in a number of
cancers, including hepatocellular, breast, and esophageal (76-79). In pancreatic
cancer, overexpression of cyclin D1 has been shown to be an indicator of poor
prognosis and is correlated with poor postoperative survival (80, 81). Cyclin D1 has
been heavily implicated in pancreatic cancer as a mechanism of chemoresistance
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by promoting cell proliferation and inhibition of drug-induced apoptosis (82-84).
Antisense knockdown of cyclin D1 allowed increased apoptosis in pancreatic, lung,
and a number of squamous cell lines. Upregulation of endogenous cyclin D1
expression through enforced transcription also inhibited apoptosis.
In prior studies in mouse embryonic fibroblasts and NIH-3T3 cells, cell cycle
arrest in the G1/S phase could be induced through activation of the of the
PERK/phospho-eIF2α/ATF4 arm of the UPR (85, 86). Cell cycle exit was mediated
by blocking cyclin D1 translation through phosphorylation of eIF2α (86).
Another study by Tomida and Tsuruo observed that A2780 (ovarian carcinoma) and
HT-29 (colon carcinoma) were also capable of downregulating cyclin D1 after being
challenged with drugs that had been shown to induce ER stress (87-90).
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CAP-DEPENDENT TRANSLATIONAL CONTROL OF GENE EXPRESSION
Gene expression is regulated at multiple levels. The final step in gene
expression is translation of mRNA. In contrast to transcriptional regulation, changes
in the translation of pre-existing mRNA’s can elicit rapid modulation of protein levels
to mediate the effects of the encoded proteins. Regulation of translation is reviewed
in detail elsewhere (91, 92). For this study, mechanisms in a process called capdependent translation initiation will be examined. The regulatory mechanisms
examined in this study involve the phosphorylation of eukaryotic initiation factor
(eIF2α) and its control of translation during stress conditions.
During cap-dependent translation, eukaryotic translation initiation factor 4E
(eIF4E) is maintained in an inactive state through inhibition by 4E-binding proteins
(4E-BPs) (Figure 2). Mitogenic stimulation, such as through the phosphoinositol-3
kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways, activate
translation by phosphorylating the 4E-BPs. Phosphorylation of 4E-BPs causes
eIF4E to be released and bind the mRNA 5’ cap. Binding of the mRNA 5’cap
recruits the 40S ribosomal subunit, which is responsible for scanning the mRNA for
an AUG initiation codon.. Recognition of the AUG initiation codon is mediated
through the ternary complex composed of the initiator Met-tRNAiMet, eIF2, and GTP.
The assembled ribosomal complex scans the mRNA until encountering an AUG
initiation codon with complementarity to the initiator Met-tRNAiMet. Recognition of
the Met-tRNAiMet to the AUG initiation codon results in irreversible hydrolysis of
GTP, and eIF2-GDP is subsequently released. A 60S ribosomal subunit then joins
the 40S subunit creating a larger 80S initiation complex which completes translation
21

of the mRNA. Activity of the ternary complex is renewed with exchange of the Gprotein from eIF2-GDP to eIF2-GTP by the guanine exchange factor eIF2B.
Phosphorylation of the α-subunit of the eIF2α results in inhibition of eIF2B, limiting
the GDP to GTP exchange (Figure 3). This serves as a rate-limiting step since
availability of the ternary complex regulates efficiency of translation efficiency.
Small differences in levels of eIF2α phosphorylation have been shown to affect
protein synthesis dramatically. In reticulocyte lysates, even a small increase in
eIF2α phosphorylation as low as 5-10% is sufficient to cause a strong abrogation of
translation (93). During conditions where eIF2 ternary complex is limited, ribosomal
“global” control of translation initiation of mRNAs is inhibited while “selective”
regulation allows translation of a particular group of mRNAs during stress
conditions. This process will be described later.
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a)

b)

Figure 2. Initiation of cap-dependent translation. a) Translation initiation
begins with formation of the cap-binding complex. Mitogenic stimulation through
pathways such as PI3K or mTOR results in phosphorylation of 4E-BP proteins.
eIF4E is released and binds the mRNA 5’cap (black circle). The 40S ribosomal
subunit is recruited. b), The ternary complex (eIF2, Met-tRNAiMet, GTP) participates
in recognizing the AUG codon and initiating protein synthesis. Exchange of GDP
for GTP by eIF2B recycles eIF2. eIF2α phosphorylation results in inhibition of
eIF2B and inhibits further translation. (Reprinted with permission from Trends in
Molecular Medicine, Calkhoven et al, December 2002) (91).
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Figure 3. Steps in translation initiation through eIF2α. Multiple stress
conditions converge at the eukaryotic initiation factor-2 complex. eIF2B acts as a
guanine exchange factor that facilitates recycling of eIF2 through exchange of GDP
for GTP. Translation is initiated when the ternary complex (eIF2, Met-tRNAiMet,
GTP) is formed. Alternatively, phosphorylation of the eIF2α subunit prevents
release of eIF2B and GDP exchange for GTP. Global protein synthesis is inhibited
while simultaneously initiating translation of stress-specific proteins. (Reprinted with
permission from Nature Reviews: Molecular Cell Biology, Holcik and Sonenberg,
April 2005) (94).
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EXPERIMENTAL RATIONALE AND HYPOTHESIS
Pancreatic cancer is one of the deadliest cancers with a poor survival rate
owing to its aggressiveness and limited treatments available. One of the key
obstacles facing treatment of pancreatic cancer is its chemoresistant nature.
Understanding of how pancreatic cancer cells have adapted mechanisms to survive
in the presence of stress is important to identifying mechanisms for sensitizing cells
to treatment.
The main hypothesis of this dissertation is that pancreatic cancer cells
have an altered endoplasmic reticulum stress response. The overall goal for
this dissertation was to determine how pancreatic cancer cells respond to ER stress
induction and how this may significantly affect chemoresistance. Since pancreatic
cancer cells demonstrate features of hypovascularity and increased proliferation,
availability of oxygen, nutrients, and glucose would be limited by vascular supply to
a rapidly growing tumor. Hypoxia and lack of nutrient availability creates an
conditions that promote induction of ER stress and activation of the unfolded protein
response. In tumors, these same conditions also select for cells which are capable
of adapting to a microenvironment of stress. Numerous studies have been
published that support the pro-tumorigenic role of the UPR. However, very little has
been published about how pancreatic cancer cells respond to induction of ER
stress.
Chapter Two aims to determine whether pancreatic cancer cells respond
similarly to ER stress induction as non-tumorigenic pancreatic ductal cells.
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Activation of two branches of the UPR will be assessed: eIF2α/ATF4/CHOP and
IRE1α/XBP1s.
Chapter Three aims to determine if altered responses to ER stress induction
in pancreatic cancer cells have UPR-mediated effects on regulation of the cell cycle.
Specifically, this aim explores translational control of cyclin D1 in pancreatic cancer
cells.
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CHAPTER TWO:
PANCREATIC CANCER CELLS HAVE AN ALTERED UNFOLDED PROTEIN
RESPONSE TO ENDOPLASMIC RETICULUM STRESS INDUCTION
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INTRODUCTION
A key feature of solid tumors is their adaptability to the environment created
by the demands of a rapidly proliferating tumor. Tumor growth creates a vast need
for oxygen and nutrients to maintain high proliferation rates. In pancreatic cancer,
however, functional vascular supply is limited with a resultant decreased capability
to deliver necessary oxygen, glucose, and nutrients to dividing tumor cells (56).
This type of environment selects for cells that are able to cope with the hypoxic and
metabolic stress created by these demands (95).
The tumor microenvironment creates conditions that predispose cells to
disturbances in endoplasmic reticulum function. The endoplasmic reticulum (ER) is
an organelle composed of an intracellular membrane network responsible for
processing of secretory and transmembrane proteins. Accumulation of unfolded or
misfolded proteins within the ER results in a perturbed homeostasis called ER
stress. In the tumor microenvironment, conditions such as oxygen or glucose
deprivation results in conditions that disrupt proper protein folding within the ER.
ER stress is subsequently induced, which leads to activation of the unfolded protein
response (UPR). The UPR is an integrated stress response pathway that is
mediated by three ER transmembrane receptors PKR-like ER kinase,
PERK/PEK/EIF2AK3, Inositol-Requiring Enzyme 1α (IRE1α), and activating
transcription factor 6 (ATF6) (96-101). These transmembrane receptors are
constitutively bound to ER chaperone GRP78 to maintain them in an inactive state.
Accumulation of protein in the ER lumen results in GRP78 release and PERK,
IRE1α, and ATF6 transduction of a stress response signal cascade to reduce
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overall protein load in the ER. This process is achieved through 1) decreased
protein translation, 2) increased expression of protein folding capacity, and 3)
upregulated degradation of misfolded proteins.
Activation of the UPR has frequently been demonstrated to provide an
adaptive mechanism for tumor cell survival in the presence of ER stress. Induction
of both the PERK/eIF2α and IRE1α/XBP1s branches of the UPR have been
implicated as playing dual roles in promoting apoptosis and survival in tumors (102).
Inhibition of translation by the PERK/ eIF2α branch is thought to reduce protein
stress and induce tumor dormancy. However, prolonged ER stress induces
apoptotic mechanisms. IRE1α/XBP1 activation has been shown to promote tumor
adaptation to hypoxia (103, 104).
Few studies have been performed to determine whether the UPR plays a
role in promoting tumor cell survival or apoptosis in pancreatic cancer. This study
aims to characterize the pancreatic cancer cell response to ER stress induction.
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MATERIALS AND METHODS
Cell lines and culture
Non-tumorigenic pancreatic cell lines human pancreatic ductal epithelial
(HPDE-E6/E7) cells were provided by Dr. M. Tsao (Ontario Cancer Institute,
Toronto, Ontario, Canada). Non-tumorigenic pancreatic nestin-positive epithelial
(hTERT-HPNE) cells and human pancreatic cancer cell lines AsPC-1, Su86.86,
Hs766T, and HPAC were obtained from American Type Tissue Collection. Human
pancreatic cancer cell lines Pa-Tu-8902, Colo357, and Pa-Tu-8988S were kind gifts
from Drs. Eric Collisson and Joe Gray (University of California and Lawrence
Livermore Laboratory, San Francisco, CA). HPDE cells were grown in keratinocyte
media that was supplemented with epidermal growth factor and bovine pituitary
extract (Invitrogen, Carlsbad, CA). For HPDE cell expansion, adherent cells were
dissociated from plastic through trypsinization, and trypsin was neutralized with
soybean trypsin inhibitor. HPNE cells were grown in Medium D as described
previously (105). All human pancreatic cancer cell lines were grown in DMEM
(Mediatech, Inc., Manassas, VA) supplemented with 10% fetal bovine serum. All
pancreatic cancer cell lines were maintained in DMEM, supplemented with 10%
fetal bovine serum. All cell lines were maintained in an incubator under conditions
of 5% CO2 at 37ºC. Cell lines were consistently maintained at confluencies of 80%
or less to minimize stress. After cells were plated and allowed to adhere overnight,
media was replaced 3-6 hours prior to start of each experiment to minimize
metabolic stress from media consumption. All cell lines were maintained in
antibiotic-free media and confirmed to be free of mycoplasma contamination by

30

testing with the Mycoalert Mycoplasma Detection Kit (Lonza BioWhittaker,
Walkersville, MD).

Reagents and antibodies
Tunicamycin (TU) was purchased from Sigma-Aldrich (St. Louis, MO). The
proteasome inhibitor bortezomib (PS-341, Velcade) was provided by Millenium
Pharmaceuticals (Boston, MA). Primary antibodies specific to the proteins were
obtained as follows: ATF4 and GRP78 (Santa Cruz Biotechnology, Santa Cruz,
CA), p27Kip1 (BD Biosciences Transduction Laboratories, San Diego, CA), total
eIF2α, (Cell Signaling Technology, Beverly, MA), phosphorylated eIF2α (Ser52)
(Invitrogen Biosource, Carlsbad, CA); β-actin (Sigma-Aldrich), CHOP (Thermo
Scientific, Rockford, IL), and XBP1-s (Biolegend, San Diego, CA). Fluorescent
secondary antibodies of IRDye CW800 goat anti-mouse, IRDye 680 goat anti-rabbit,
andn IRDye 680 donkey anti-goat were purchased from Li-cor Biotechnology
(Lincoln, NE).

Immunoblotting
Cells were lysed for 15 minutes on ice in Triton-X lysis buffer [1% Triton X100, 150 mmol/L sodium chloride, 25 mmol/L Tris (pH 7.5), 1 mmol/L glycerol
phosphate, 1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride and
protease inhibitor cocktail (Sigma)], collected by scraping, and incubated on ice an
additional 10 minutes. Lysates were sonicated briefly and centrifuged at 14,000 x g
at 4ºC for 15 minutes to clear cellular debris. 40 μg of total cellular protein of each
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sample was loaded with 4X sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer to a final concentration of 50 mmol/L
Tris-HCl, 2% SDS, 10% glycerol, 0.01% bromophenol blue, and 5% βmercaptoethanol. Samples were heated to 95ºC for 5 minutes, resolved by SDSPAGE, and subsequently transferred to nitrocellulose membranes. Membranes
were blocked with either 5% nonfat milk in phosphate-buffered saline (PBS) or 3%
bovine serum albumin (BSA) in tris-buffered saline (TBS) for antibodies detecting
phosphorylated proteins for 1 hour. Blots were then incubated with primary
antibodies overnight at 4ºC, washed, and probed with the appropriately targeted
species of secondary antibody. Protein bands were visualized and quantified using
the Odyssey Infrared Imaging System and manufacturer-supplied software (Li-Cor
Biotechnology). For most membranes, more than one primary antibody was coincubated and visualized using the Odyssey two-color detection system.
[6-3H]-Thymidine Incorporation Assays
Selected cell lines were plated in 96-well plates so that the confluency of
cells in the DMSO-treated control wells reached approximately 70-80% at the
conclusion of the experiment. Cells were allowed to adhere over 24 hours. 3-6
hours prior to experiment start, media was replaced with fresh warmed media to
minimize metabolic stress from media consumption. Cells were exposed to DMSO
or 0.001, 0.01, 0.02, 0.04, 0.08, 0.16, 0.3, and 0.6 μg/ml tunicamycin for 48 hours.
After treatment, cells were gently washed with PBS once and then pulse-labeled
with 10 μCi/ml [6-3H] thymidine (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ) for 1 hour at 37ºC under normoxic conditions in an incubator. Non32

incorporated [6-3H] thymidine was removed by gently washing cells with PBS once.
Cells were then lysed in 100 μl of 0.1 M KOH and harvested onto fiberglass filters
using a plate harvester. Incorporated tritiated thymidine was quantified using a
scintillation counter.

Quantification of DNA Fragmentation
Analysis of DNA fragmentation was performed through propidium iodide (PI)
staining. Selected cell lines were plated in 6-well plates so that the final confluency
of cells in the control wells reached approximately 70-80%. Cells were allowed to
adhere overnight. 3-6 hours prior to experiment start, media was replaced with
fresh warmed media to minimize metabolic stress from media consumption. After
exposure to various treatments, cells were harvested with 0.05% trypsin-EDTA,
neutralized with serum-containing media and centrifuged at 500 x g. Cell pellets
were washed twice with PBS, pelleted again by centrifugation, and fixed at least
overnight in 70% ice-cold ethanol at 4ºC. Cells were then centrifuged at 1000 x g
for 5 minutes and incubated in 50 μg/ml PI with 10 μg/ml RNase A for 30 minutes at
room temperature while protected from light. Subsequent flow cytometric analysis
was performed on a Beckman Coulter XL (Brea, CA) at the University of Texas
M.D. Anderson Cancer Center’s Flow Cytometry and Cellular Imaging Facility
(Houston, TX). Cells in the sub-G0/G1 peak were considered apoptotic. The
remaining cells were assessed for the percentage of cells in each of the cell cycle
phases. Cell cycle analysis results were normalized to the DMSO-treated control
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where proportion of cells in each phase was represented as a percentage of the
DMSO-treated control unless otherwise specified.
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RESULTS
Pancreatic cancer cells reduced inhibition of DNA synthesis after tunicamycin
treatment compared to non-tumorigenic cells.
Evidence exists that the unfolded protein response pathways can play a
cytoprotective role, particularly in adaptation to hypoxic stress (58, 104). The
endoplasmic reticulum stress response in pancreatic cancer cells has not been
previously assessed. To activate the UPR, the classic ER stressor tunicamycin was
used as a tool to induce ER stress through its inhibition of dolichol-mediated
synthesis of glycoproteins, which disrupts protein exit from the ER. To determine
whether pancreatic cancer cells exhibit a different response to protein load
induction, pancreatic cancer cells were exposed to a dose-dependent increase of
tunicamycin for 48 hours. DNA synthesis was assessed through the incorporation
of thymidine radioactively labeled with tritium and was used as an indirect measure
of cell proliferation. At all doses ≥0.01 μg/ml tunicamycin, pancreatic cancer cell
lines exhibited a statistically significant difference (p<0.01) in DNA synthesis rates
compared to non-tumorigenic cells (Figure 4). Pancreatic cancer cell lines fail to
reach comparable inhibition of DNA synthesis up to a dose of 0.6 μg/ml
tunicamycin. A dose of 0.5 μg/ml tunicamycin was chosen for further experiments
to evaluate the ER stress response in non-tumorigenic and pancreatic cancer cells.
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[H3] Thymidine Uptake
(% of DMSO Control)

Non-Tumorigenic
HPDE
HPNE

200
150

Cancer
Hs766T
Su86.86
Colo357
Pa-Tu-8902
Pa-Tu-8988S

100
50
DMSO
0.001

0.5 1
0.01
0.1
Tunicamycin (µg/ml)
Treatment at 48 hours

Figure 4. Pancreatic cancer cells have dose-dependent reduced inhibition of
DNA synthesis with tunicamycin. Non-tumorigenic (pink curves, HPDE, HPNE)
and pancreatic cancer cell lines (green curves, Hs766T, Su86.86, Colo357, Pa-Tu8902, Pa-Tu-8988S) were exposed to increasing doses from 0.001 μg/ml to 0.6
μg/ml tunicamycin for 48 hours. Growth curves were measured through [6-3H]thymidine uptake. p<0.01 with 2-way ANOVA and Bonferroni post-test comparing
each non-tumorigenic cell line to each pancreatic cancer cell line for all
concentrations ≥0.01 μg/ml tunicamycin. A tunicamycin dose of 0.5 μg/mL was
chosen for further experiments. All experiments were repeated in at least 3
separate experiments, n=3. Error bars represent SEM.

36

Pancreatic cancer cells have delayed phosphorylation of eIF2α.
Tunicamycin treatment (0.5 μg/ml) in non-tumorigenic pancreatic ductal cells
elicited a prompt phosphorylation of eIF2α within a minimal treatment duration of 2
hours. This rapid response was in contrast to pancreatic cancer cells requiring at
least 8 hours of exposure before a clear increase in phosphorylation was induced.
Non-tumorigenic cells had a greater magnitude of maximal phosphorylation with 2fold (HPDE) or 4-fold (HPNE) induction by 4 hours. Of the three pancreatic cancer
cell lines tested, HPAC reached the greatest magnitude of phosphorylation
induction with a maximal induction of only 1.5-fold induction by 12 hours (HPAC).
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A)

Figure 5. Phosphorylation of eIF2α is delayed in pancreatic cancer cells
compared to non-tumorigenic pancreatic ductal cell lines. Treatment time
courses over 24-hour incubation period of tunicamycin treatment. “D” represents
treatment with DMSO vehicle over 24 hours. A, non-tumorigenic pancreatic cell
lines HPDE and HPNE rapidly phosphorylate eIF2α within 2 hours of tunicamycin
treatment. B (next page), pancreatic cancer cell lines Pa-Tu-8902, HPAC, and
AsPC-1 display delayed and markedly diminished phosphorylation of eIF2α.
Each experiment was repeated in at least 2 separate experiments.
Representative immunoblots are shown of similar data.
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B)
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Pancreatic cancer cells have delayed induction of ATF4.
Transmission of the delayed activation of the eIF2α arm of the UPR resulted
in the delayed induction of the downstream effector ATF4. ATF4 is selectively
translated while global protein synthesis is inhibited via eIF2α phosphorylation
during ER stress. Consistent with phosphorylation of eIF2α, ATF4 was upregulated
as early as 2 hours in non-tumorigenic cell lines HPDE and HPNE. In contrast,
expression of ATF4 did not occur before 8 hours in pancreatic cancer cell lines. In
addition to the delayed rate of ATF4 induction, pancreatic cancer cell lines also
exhibited a diminished degree of induction. This altered response is most obvious
when compared to the same positive control (Figure 6). Each immunoblot was
loaded with the same lysate of HPNE that was treated with 100 nM bortezomib for 4
hours as a positive control for antibody effectiveness (106). ATF4 was robustly
expressed in non-tumorigenic cell lines while pancreatic cancer cell lines had low
induction, particularly in HPAC and AsPC-1 cells.
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A)

Figure 6. ATF4 induction is delayed in pancreatic cancer cells compared to
non-tumorigenic pancreatic ductal cell lines. Treatment time courses over 24hour incubation period of tunicamycin treatment. A, non-tumorigenic pancreatic cell
lines HPDE and HPNE exhibit early induction of ATF4 within 2 hours of tunicamycin
treatment. B (next page), pancreatic cancer cell lines Pa-Tu-8902, HPAC, and
AsPC-1 display delayed and markedly diminished induction of ATF4, particularly
when compared to the same positive control. The DMSO-treated vehicle control,
“D”, for each cell line was treated for 24 hours. Positive control for antibody
effectiveness: protein lysate from HPNE cells treated with 100 nM bortezomib for 4
hours. Each experiment was repeated in a minimum of 2 repetitions.
Representative immunoblots are shown of similar data.
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B)

42

Pancreatic cancer cells have delayed induction of CHOP.
Further assessment of events downstream of activation of the eIF2α arm of
the UPR demonstrated that in addition to delayed activation of eIF2α and ATF4,
CHOP was also delayed in its expression. Selective translation of ATF4 following
ER stress induction resulted in transcription of its target gene, CHOP/GADD153.
Consistent with a late activation of the eIF2α and ATF4 pathways, CHOP
expression was also delayed in pancreatic cancer. CHOP expression occurred in
non-tumorigenic pancreatic cells at a minimum of 3-4 hours compared to 8 hours in
pancreatic cancer cells.

The duration of CHOP expression was relatively similar in

both non-tumorigenic and cancer cell lines with a prolonged induction to 24 hours of
tunicamycin treatment.
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A)

Figure 7. CHOP induction is delayed in pancreatic cancer cells compared to
non-tumorigenic pancreatic ductal cell lines. Treatment time courses over 24hour incubation period of tunicamycin treatment. A, non-tumorigenic pancreatic cell
lines HPDE and HPNE exhibit early induction of CHOP within 4 hours of
tunicamycin treatment. B (next page), pancreatic cancer cell lines Pa-Tu-8902,
HPAC, and AsPC-1 display delayed induction of CHOP within 8 hours of
tunicamycin incubation. Each experiment was repeated in a minimum of 2
repetitions. Representative immunoblots are shown of similar data. The DMSOtreated vehicle control, “D”, for each cell line was treated for 24 hours.
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B)
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Pancreatic cancer cell lines have reduced ability to activate the IRE1α/XBP1S
arm of the UPR.
After establishing that the eIF2α/ATF4/CHOP arm of the UPR was late
activated late in pancreatic cancer cells, I wanted to assess further whether
impairment was isolated to the eIF2α arm of the UPR or generalized to the other
branches of the UPR. Therefore, I next examined whether the IRE1α response to
ER stress was also delayed. As a read-out for activation of IRE1α, I assessed
whether expression of its downstream cleavage product, spliced XBP-1 (XBP1s),
occurred late in pancreatic cancer cells compared to non-tumorigenic cells. IRE1α
mediates splicing of the uncleaved precursor mRNA of XBP-1, the only identified
cleavage product of the IRE1α endoribonuclease function. Clear visualization of
XBP-1 splicing in pancreatic cancer cells did not occur until a minimum of 8 hours
compared to as little as 3 hours for non-tumorigenic pancreatic ductal cells.
Interestingly, non-tumorigenic cells reached a distinct peak of XBP1s expression at
8 hours, which rapidly diminished by 24 hours. In marked contrast, expression of
XBP1s persisted from 8 hours until the end of the time course at 24 hours in
pancreatic cancer cells.
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A)

Figure 8. XBP1s expression is delayed in pancreatic cancer cells
compared to non-tumorigenic pancreatic ductal cell lines. Treatment
time courses over 24-hour incubation period of tunicamycin treatment. A,
non-tumorigenic pancreatic cell lines HPDE and HPNE exhibit early
induction of XBP1s within 3 hours of tunicamycin treatment. Rise in
XBP1s expression peaks at 8 hours and declines rapidly by 24 hours. B
(next page), pancreatic cancer cell lines Pa-Tu-8902, HPAC, and AsPC-1
display delayed induction of XBP1s, requiring at least 8 hours of
tunicamycin incubation. Activation of XBP1s remained elevated from 8
hours until 24 hours. Each experiment was repeated in a minimum of 2
separate experiments. Representative immunoblots are shown of similar
data. The DMSO-treated vehicle control, “D”, for each cell line was treated
for 24 hours. Positive control for antibody effectiveness: protein lysate
from HPDE cells treated with 10 μg/ml tunicamycin for 8 hours.
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GRP78 response is similar in pancreatic cancer cells and non-tumorigenic
pancreatic ductal cells
We next investigated GRP78 expression as a potential explanation for the
impairment of both for eIF2α and IRE1α/XBP1s arms of the UPR. Since both UPR
arms were affected, the cause of this impairment was likely upstream of both
pathways. Since GRP78 constitutively binds the UPR transmembrane receptors to
maintain them in an inactive state, upregulation of GRP78 could possibly require an
increased threshold of protein load in the ER before PERK and IRE1α could be
activated. GRP78 could also act as an adaptive mechanism once ER stress was
induced to increase capacity for protein load. Consequently, we would expect
either an increased basal expression of GRP78 prior to ER stress or an increased
GRP78 induction once ER stress occurred to counter the accumulation of ER
proteins.
However, we observed that in contrast to delayed responses in both
eIF2α/ATF4/CHOP and IRE1α/XBP1s branches, no clear differences in
upregulation of GRP78 were observed between non-tumorigenic and pancreatic
cancer cells. In previously performed studies (negative data not shown), no
consistent differences between non-tumorigenic and pancreatic cancer cell lines
were observed. Similar responses to activation of GRP78 occurred in both
pancreatic cancer cells and non-tumorigenic cells. Both HPDE and HPNE cells had
a similar rate of GRP78 induction to pancreatic cancer cells with clear upregulation
occurring at 12 hours. Upregulation of GRP78 in pancreatic cancer cells occurred
at variable intervals, ranging from a minimum of 8 hours (HPAC) up to 18 hours
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(AsPC-1). The maximum reached induction level from baseline for GRP78
expression was also similar among non-tumorigenic pancreatic ductal cells and
pancreatic cancer cells. Both types of cell lines upregulated GRP78 by 2-4 times
the baseline value over 24 hours.
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A)

Figure 9. GRP78 expression is similar in both pancreatic cancer cells
and non-tumorigenic pancreatic ductal cell lines. Treatment time courses
over 24-hour incubation period of tunicamycin treatment. A, non-tumorigenic
pancreatic cell lines HPDE and HPNE exhibit induction of GRP78 at 8 hours
of tunicamycin treatment. B (next page), pancreatic cancer cell lines Pa-Tu8902, HPAC, and AsPC-1 display induction of GRP78 between 8 and 18
hours of tunicamycin incubation. Each experiment was repeated in a
minimum of 2 repetitions. Representative immunoblots are shown of similar
data. The DMSO-treated vehicle control, “D”, for each cell line was treated
for 24 hours.
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B)
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Treatment with tunicamycin does not induce apoptosis in most cell lines.
To assess whether cells were being lost to apoptosis during the duration of
tunicamycin treatment, rates of apoptosis were determined at 24 hours. ER stress
normally activates a pro-survival response initially in cells by activating mechanisms
that mitigate protein stress within the ER. However, apoptosis is induced if the cell
is unable to reduce the protein load. The pro-apoptotic switch of the UPR is thought
to occur through induction of CHOP and subsequent activation of caspases. As
demonstrated by Figure 10, neither non-tumorigenic nor pancreatic cancer cells
underwent any statiscally significant apoptosis greater than their respective DMSOtreated controls after treatment with tunicamycin. The exception to this observation
was pancreatic cancer cell line HPAC. Longer durations up to 24 hours of
tunicamycin exposure induced 16.3 +/- 5.2% apoptosis. Preliminary time course
studies indicate that apoptosis of more than 10% did not occur until after 16 hours
of tunicamycin exposure (data not shown).
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Figure 10. Most non-tumorigenic pancreatic ductal and pancreatic cancer
cell lines do not undergo apoptosis following tunicamycin treatment. Cell
death measured via propidium iodide staining and quantified by flow cytometry.
Cells in the sub-G0/G1 were considered apoptotic. Non-tumorigenic pancreatic
ductal cells (in pink hues, HPDE, HPNE) and pancreatic cancer cells (in blue hues,
Pa-Tu-8902, HPAC, AsPC-1) were treated with DMSO vehicle or tunicamycin (0.5
μg/ml) for 24 hours. Columns, n=3; bars represent SEM.
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DISCUSSION
This study aimed to determine whether the pancreatic cancer cell lines
regulated the unfolded protein response differently from non-tumorigenic cells. Our
research demonstrates that pancreatic cancer cell lines possess a deficient ability to
activate either the eIF2α/ATF4/CHOP or IRE1α/XBP1s arms of the UPR.

The

identification of two branches that fail to be activated by ER stress induction
indicates that a global response to UPR activation is impaired.

This finding

implicates a defect upstream of the UPR branches.
The failure to activate the UPR could represent a number of problems within
the cell. The two most salient explanations for a deficient UPR response would be
either an overall failure to detect ER stress or a pre-existing compensatory
mechanism enabling the cells to handle a higher protein capacity at basal
conditions. The current prevailing theory of how the UPR is activated is through
disinhibition of the UPR transmembrane “sensors” through GRP78 release.
Conceivably, the presence of inactivating mutations or the presence of one or more
inhibitory proteins could exist for either PERK or IRE1α in pancreatic cancer cells.
Such inactivating mutations or interacting proteins preventing their oligomerization
or autophosphorylation could make the cells less responsive to ER stress because
the UPR sensors would be inhibited. Consequently, cells would be less sensitive to
detection of protein stress within the ER.

However, the presence of mutations in

both PERK and IRE1α would seem to be highly improbable. While PERK mutations
do exist in humans (Wolcott-Rallison Syndrome), this seems to be an unlikely
explanation since PERK mutation has not been specifically linked to the
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development of cancer (107). Studies in mice with established germline mutations
in PERK have demonstrated diabetes along with a number of systemic
abnormalities, such as osteoporosis and growth retardation (108). Conceivably, the
observance of pancreatic β-cell deficiency with PERK mutation could be an
explanation for the high incidence of diabetes in pancreatic cancer patients, but this
was beyond the scope of this study. The alternative possibility of a binding protein
that modulates PERK and IRE1α activity is most logically filled by the role of
GRP78.

However, my studies indicate that induction rate and the degree of

induction of GRP78 is similar among non-tumorigenic and pancreatic cancer cell
lines. Additionally, I previously performed studies which indicated no significant
difference in basal GRP78 protein expression between non-tumorigenic and
pancreatic cancer cells (negative data not shown). Other proteins that may interact
with both molecules have not been identified.
The second possible explanation for defective eIF2α activation is a
mechanism enabling a higher protein load before the UPR is activated.

Past

research has indicated that a decreased ability to phosphorylate eIF2α promotes
cell transformation (109-112).

Seemingly contrary to this finding, most recent

evidence indicates that the PERK/eIF2α pathway acts as a cytoprotective
mechanism by mitigating the increased protein stress placed on proliferating tumor
cells (58, 61-64). Deficiency of PERK activity has been repeatedly shown to induce
apoptosis cells because of the failure to abrogate protein synthesis, thus creating an
environment of toxic protein stress. While our study may appear inconsistent with
the most recent studies, we propose that pancreatic cancer cells possess an
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adaptive mechanism upstream of the UPR that pre-empts the need for its protective
effects in pancreatic cancer cells. We propose that a pre-existing over-abundance
protein folding mechanisms, such as ER chaperones, would prevent protein
aggregation. An increase in such mechanisms may essentially act as a protein
“buffer” system that allows a higher protein capacity within the cell before stress is
induced. Upregulation of a number of ER chaperones, such as GRP78 or GRP94,
have indeed been documented to be upregulated in multiple cancers (113). This
concept is supported by a previous study by Yamaguchi et al, which established a
link between ER chaperone levels with delayed responses in the UPR (114). They
demonstrated that HEK293 cells with a kinase-dead PERK demonstrated an overabundance of calreticulin, a chaperone involved in maintaining ER protein quality
control, at both basal and after ER stress induction. Deficiency in PERK function
resulted in complete block of ATF4 expression and delayed induction of CHOP
(114). These findings are remarkably similar to my results where a deficient eIF2α
response also resulted in delayed and diminished activation of ATF4 and slower
induction of CHOP in pancreatic cancer cell lines.
To determine whether the altered response to ER stress induction was
isolated to the eIF2α arm of the UPR, I further examined the IRE1α/XBP1s
signaling. I identified that in addition to delayed activation of the eIF2α arm of the
UPR, activation of the IRE1α branch was also delayed. XBP1 splicing was utilized
as a readout for IRE1α activation. We found that XBP1s expression persisted in
pancreatic cancer cells even up to 24 hours of treatment. This is in comparison to
non-tumorigenic cell lines where XBP1s expression quickly increased up to 8 hours
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with a rapid decline by 12 hours. Once activated, the IRE1-XBP1s pathway
appears to elicit a full and sustained response. This increase in XBP1s expression
may represent a compensatory increase in activation of an alternative UPR pathway
given the continued deficiency in phosphorylation of the eIF2α pathway. Despite a
delay in the initial activation of this response, the persistent expression of XBP1s in
pancreatic cancer cells may be a pro-tumorigenic activation of the UPR that
indicates more than a shift in the protein load capacity of these cells. XBP1s
activation may represent a true deficiency in the phosphorylation of eIF2α. These
findings are supported with previous findings where Perk-deficient embryonic stem
cells demonstrated persistent IRE1α activation up to 16 hours while subsiding within
4-6 hours in their wild-type counterparts (60). Interestingly, the XBP1s pathway has
been frequently attributed to promoting mostly pro-tumorigenic functions.
Expression of XBP1s was shown to be correlated with hypoxic regions tumor and
was demonstrated to be critical to tumor growth under hypoxic conditions (104).
XBP1s has also been shown to regulate survival-promoting pathways that
upregulate ER chaperones and ER biogenesis. These findings suggest that
possibly two mechanisms of adaptability to ER stress induction exist: increased
tolerance to UPR activation and compensatory XBP1s activation once the threshold
for its activation is reached.
One mechanism that warrants further investigation is the possibility that
autophagy may play a role in protecting pancreatic cancer cells from ER stress.
Autophagy entails another process with dual cytoprotective and cytotoxic functions.
The cytoprotective component of autophagy attempts to counter proteotoxic stress
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in cells by sequestration of proteins away from the cellular environment into
autophagosomes.

Autophagy has been consistently shown to be activated in

response to ER stress as a complementary mechanism to the UPR to alleviate
protein stress (61). Inhibition of this process has been shown to enhance cell death
by eliminating a pathway for preventing protein accumulation, thus creating a toxic
cellular environment. Although propidium iodide staining revealed that in most nontumorigenic and pancreatic cancer cell lines did not undergo a significant amount of
cell death, autophagy may play a role in ameliorating protein stress by storage of
proteins into autophagosomes.

However, the delayed activation of the eIF2α

pathway would appear to argue against the presence of accumulated proteins and
autophagy unless a defect in ER stress detection existed. Additionally, ATF4 has
been implicated as a potential mechanistic link from the UPR to autophagy that
helps mediate adaptation of tumor cells to hypoxic stress (58, 115). However, in my
studies, the late and reduced activation of ATF4 would suggest that autophagy were
not being induced through ATF4 in pancreatic cancer cells.
Tunicamycin treatment did not induce significant apoptosis compared to their
DMSO-treated controls in non-tumorigenic cell lines and 2 out of 3 pancreatic
cancer cell lines. Ironically, protection from apoptosis by two different mechanisms
is likely occurring in non-tumorigenic compared to pancreatic cancer cell lines.
Non-tumorigenic cells were capable of phosphorylating eIF2α and effectively
reducing protein load. This mechanism of translational attenuation has been
repeatedly shown to promote cell survival by preventing continued protein
accumulation through translational inhibition (60, 116). One pancreatic cancer cell
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line, HPAC, was the only cell line to exhibit sensitivity to apoptosis induction by
tunicamycin treatment (Figure 10). However, preliminary evaluation of apoptosis
induction through a time course over 24 hours revealed that significant induction of
apoptosis to more than 10% required at least 20 hours of tunicamycin treatment
(data not shown). The limited apoptosis observed up to that time point would
suggest that HPAC cells were able to accommodate increased protein load. An
explanation for this observation could possibly be attributed to defects in autophagy
activation. If defects in the autophagy pathway existed, especially in conjunction
with a defective activation of translational repression via the eIF2α pathway, toxic
proteins could accumulate in the cellular environment. HPAC cells would likely be
less capable of handling the excess protein. In the presence of ineffective eIF2αmediated translational repression, more proteins would continue to be synthesized
and further contribute to protein accumulation. Consequently, excess and
malfolded proteins would be free to aggregate within the cell creating a toxic
microenvironment, resulting in increased cell death.
The differing response in HPAC may suggest a potential susceptibility of a
subset of pancreatic cancer cell lines to ER stress that is not encountered in nontumorigenic cells.

While HPAC cells exhibited similar delayed activation of the

UPR, these cells appeared to be more prone to apoptosis. This finding is more
consistent with published studies indicating that a deficient phosphorylation of eIF2α
resulted in continued protein synthesis and overwhelming protein load (60, 117).
These results would suggest that HPAC cells may have a truly deficient eIF2α
activation once the threshold for ER stress is achieved. Conjecture would suggest
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that while HPAC cells still possess a compensatory mechanism for accommodating
increased protein load, saturation of this system results in overwhelming protein
stress that cannot be relieved by translational attenuation through a deficient eIF2α
response.
While this study did not find a primary cause for the deficient activation of the
UPR, identification of the explanation for this finding could lead to potential new
targets that would enable pancreatic cancer cells to be sensitized to ER stressinducing agents.

Admittedly, a key problem with targeting ER stress in cancer

therapy is the lack of specificity in differentiating normal from cancer cells.
Proteasomal inhibitors, such as bortezomib, appear to have partially circumvented
this problem in some aspects by selectively inducing ER stress-mediated apoptosis
in tumor cells because of their high protein turnover rate. In pancreatic cancer cells,
bortezomib has been shown to induce ER stress-mediated apoptosis (66, 67, 118).
The narrow therapeutic index between inducing apoptosis in normal versus cancer
cells impedes an effective cancer-specific strategy that does not also create toxicity.
This obstacle is no more evident than in pancreatic cancer.

A critical problem

frequently encountered in the treatment of pancreatic cancer is balancing the
toxicity induced by chemotherapies compared to the therapeutic benefit obtained. I
suspect that a component of the chemoresistance encountered along with the poor
toxicity profile of chemotherapeutics in pancreatic cancer is due to an elevated
tolerance for protein stress, as supported by my study.

I hypothesize that

pancreatic cancer cells are able to withstand such a high level of protein stress
before the induction of the ER stress response that it far exceeds the protein stress
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capacity of normal cells. My previous studies have yet to identify any level of basal
ER

stress

in

pancreatic

cancer

cells

despite

a

hypovascular

tumor

microenvironment that should predispose cells to ER stress induction (negative data
not shown). I suspect that ER stress is not induced at basal levels in part because
an adaptive mechanism to higher protein load exists in pancreatic cancer cells.
Identification of a cancer-specific target that “shifts the curve” toward a threshold
level of protein stress in pancreatic cancer cells that would essentially sensitize the
cells to earlier induction of ER stress. I propose that rather than identifying agents
that act as single chemotherapeutic therapies, ER stress-targeting agents should be
used in combination therapy to “prime” cells for sensitization ER stress-mediated
apoptosis by other tumor selective agents.
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CHAPTER THREE:
CYCLIN D1 REGULATION IN PANCREATIC CANCER CELLS IS IMPAIRED IN
RESPONSE TO ER STRESS
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INTRODUCTION
Loss of cell cycle control is thought to be an important component of
tumorigenesis in cancer. Cyclin D1 has been shown to be overexpressed in
multiple cancers, including in pancreatic cancer (77-80, 119). Its overexpression in
pancreatic cancer has been associated with poor prognosis (80). In up to 90% of
pancreatic tumors, KRAS is mutated to an oncogenic isoform and results in a
constitutively activated RAS-RAF-MEK pathway. The tumorigenic effects of this
activating mutation has been well-established as a promoter of cyclin D1
transcription, cyclin D1 protein translation and stability, and assembly of cyclin D1
holoenzyme complexes with CDK4 and CDK6 (120-124).
In malignancy, the dysregulation of cyclin D1 and subsequent uncontrolled
tumor cell proliferation is driven at multiple regulatory levels, including
transcriptional, translational, and post-translational regulation steps. The
uncontrolled growth of these transformed cells places strenuous requirements on
solid tumors to supply adequate oxygen and nutrients to rapidly growing tumors. In
poorly vascularized tumors such as pancreatic adenocarcinoma, hypoxic stress,
nutrient and glucose deficiency, as well as altered calcium homeostasis are thought
to promote signaling pathways required to sustain continued tumor growth. One
such pathway known to respond to these increased metabolic and hypoxic stresses
is endoplasmic reticulum stress. As a cytoprotective mechanism in normal cells, ER
stress induction activates a UPR-mediated translational attenuation, which has
been previously shown to reduce translation of cyclin D1 and lead to subsequent
cell cycle arrest (85, 86). An expected response to increased metabolic demand in
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a pancreatic tumor would be reduction of cyclin D1 through the UPR. Contradictory
to this, however, previous studies have established that pancreatic cancer cells
demonstrate increased cyclin D1 expression.
I hypothesized that pancreatic tumors are unable to downregulate cyclin D1
translation in response to endoplasmic reticulum stress and that this impaired
repression was mediated through an eIF2α-dependent mechanism. Previous
findings from Chapter Two identified an altered unfolded protein response in
pancreatic cancer cells to ER stress induction. In this study, I challenged pancreatic
cancer cells with two classical ER-inducing stress agents, tunicamycin and
thapsigargin, to investigate the response of pancreatic cancer cells to ER stress. I
found that in comparison to non-tumorigenic pancreatic cells, a subset of pancreatic
cancer cells were consistently unable to downregulate cyclin D1 and exit the cell
cycle after ER stress induction. Further analyses demonstrated that this delayed
inhibition of cyclin D1 levels was due to impaired translational repression mediated
by the eIF2α pathway of the UPR. These findings suggest that a subset of
pancreatic cancer cells have increased tolerance to ER stress-mediated cell cycle
arrest.
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MATERIALS AND METHODS
Cell lines and culture
Non-tumorigenic cell line human pancreatic ductal epithelial (HPDE-E6/E7)
cells was provided by Dr. M. Tsao (Ontario Cancer Institute, Toronto, Ontario,
Canada). The human pancreatic nestin-positive epithelial (hTERT-HPNE) cell line
was obtained from the American Type Tissue Collection. 22 pancreatic cancer cell
lines were initially screened in this study: human pancreatic cancer cell lines AsPC1, Hs766T, BxPC3, MiaPaca-2, Su86.86, HPAC (American Type Tissue Collection);
MPanc96 (Dr. Timothy J. Eberlein, Washington University, St. Louis, MO); L3.6pl
(Dr. Isaiah J. Fidler, MD Anderson Cancer Center, Houston); SW1990, SUIT-2,
T3M4, DAN-G, COLO357, Pa-Tu-8902, Pa-Tu-8988T, HCG-25, 3.27, 2.03, HPAFII,
CAPAN2, and CFPAC1 (Drs. Joe Gray, Eric Collison, and Martin McMahon,
University of California and Lawrence Livermore Laboratory, San Francisco, CA).
HPDE cells were grown in keratinocyte media and supplemented with epidermal
growth factor and bovine pituitary extract (Invitrogen, Carlsbad, CA). For HPDE cell
expansion, adherent cells were dissociated from plastic through trypsinization, and
trypsin was neutralized with soybean trypsin inhibitor. HPNE cells were grown in
Medium D as described previously (105). All human pancreatic cancer cell lines
were maintained in DMEM (Mediatech, Inc., Manassas, VA) supplemented with
10% fetal bovine serum. Wild-type eIF2α mouse embryonic fibroblasts (MEFs) and
mutant eIF2α (S51A) MEFs with a non-phosphorylatable eIF2α at serine 51 were
generously provided by David Ron (New York University, New York, NY). S51A
and WT MEFs were maintained in DMEM (Mediatech, Inc., Manassas, VA),
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supplemented with 10% fetal bovine serum, 10 μmol/L non-essential amino acids
(Lonza BioWhittaker, Walkersville, MD), 0.55 μmol/L β-mercaptoethanol (Sigma, St.
Louis, MO), and L-glutamine (Lonza BioWhittaker, Walkersville, MD). All cell lines
were maintained in an incubator under conditions of 5% CO2 at 37ºC. Cell lines
were consistently maintained at confluencies of 80% or less to minimize stress.
After cells were plated and allowed to adhere overnight, media was replaced 3-6
hours prior to start of each experiment to minimize metabolic stress from media
consumption. All cell lines were maintained in antibiotic-free media and confirmed
to be free of mycoplasma contamination by testing with the Mycoalert Mycoplasma
Detection Kit (Lonza BioWhittaker, Walkersville, MD).

Reagents and antibodies
Tunicamycin (TU) and cycloheximide (CHX) was purchased from SigmaAldrich (St. Louis, MO). Thapsigargin (TG) was obtained from EMD Chemicals
(Gibbstown, NJ). The proteasome inhibitor bortezomib (PS-341, Velcade) was
provided by Millenium Pharmaceuticals (Boston, MA). Primary antibodies specific
to the proteins were obtained as follows: cyclin D1 (Santa Cruz Biotechnology,
Santa Cruz, CA), p27Kip1 (BD Biosciences Transduction Laboratories, San Diego,
CA), phospho-Rb, total Rb, phospho-GSK3α/β, total GSK3β (Cell Signaling
Technology, Beverly, MA). Fluorescent secondary antibodies of IRDye CW800
goat anti-mouse and IRDye 680 goat anti-rabbit were purchased from Licor
Biotechnology (Lincoln, NE).
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Cell Cycle Analysis
Analysis of cell cycle phases and DNA fragmentation were performed
through propidium iodide (PI) staining. Selected cell lines were plated in 6-well
plates so that the final confluency of cells in the control wells reached approximately
60-70%. Cells were allowed to adhere overnight. 3-6 hours prior to experiment
start, media was replaced with fresh warmed media to minimize metabolic stress
from media consumption. After exposure to various treatments, cells were
harvested with 0.05% trypsin-EDTA, neutralized with serum-containing media and
centrifuged at 500 x g. Cell pellets were washed twice with PBS, pelleted again by
centrifugation, and fixed at least overnight in 70% ice-cold ethanol at 4ºC. Cells
were then centrifuged at 1000 x g for 5 minutes and incubated in 50 μg/ml PI with
10 μg/ml RNase A for 30 minutes at room temperature while protected from light.
Subsequent flow cytometric analysis was performed on a Beckman Coulter XL
(Brea, CA) at the University of Texas M.D. Anderson Cancer Center’s Flow
Cytometry and Cellular Imaging Facility (Houston, TX). Cells in the sub-G0/G1
peak were considered apoptotic. The remaining cells were assessed for the
percentage of cells in each of the cell cycle phases. Cell cycle analysis results were
normalized to the DMSO vehicle control where the proportion of cells in each phase
was represented as a percentage of the DMSO-treated control unless otherwise
specified.

68

Immunoblotting
Cells were lysed for 15 minutes on ice in Triton-X lysis buffer [1% Triton X100, 150 mmol/L sodium chloride, 25 mmol/L Tris (pH 7.5), 1 mmol/L glycerol
phosphate, 1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride and
protease inhibitor cocktail (Sigma)], collected by scraping, and incubated on ice an
additional 10 minutes. Lysates were sonicated briefly and centrifuged at 14,000 x g
at 4ºC for 15 minutes to clear cellular debris. 40 μg of total cellular protein of each
sample was loaded with 4X sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer to a final concentration of 50 mmol/L
Tris-HCl, 2% SDS, 10% glycerol, 0.01% bromophenol blue, and 5% βmercaptoethanol. Samples were heated to 95ºC for 5 minutes, resolved by SDSPAGE, and subsequently transferred to nitrocellulose membranes. Membranes
were blocked with either 3% bovine serum albumin (BSA) in tris-buffered saline
(TBS) for detection of phosphorylated proteins or 5% nonfat milk in phosphatebuffered saline (PBS) for 1 hour. Blots were then incubated with primary antibodies
overnight at 4ºC, washed, and probed with the appropriately targeted species of
secondary antibody. Protein bands were visualized and quantified using the
Odyssey Infrared Imaging System and manufacturer-supplied software (Li-Cor
Biotechnology). For most membranes, more than one primary antibody was coincubated and was visualized using the two-color detection system.

69

Real-Time Quantitative Polymerase Chain Reaction
Total RNA was collected and isolated in Trizol reagent (Invitrogen, Carlsbad,
CA) per manufacturer’s protocol. 1 μg of total mRNA was subjected to genomic
DNA elimination treatment and reverse transcribed for 30 minutes using the
QuantiTect Reverse Transcription Kit by Qiagen (Hilden, Germany) following
manufacturer’s instructions. The resulting cDNA was diluted 1 volume to 10
volumes. Subsequently, quantitative PCR was performed with reaction mixtures
consisting of 1 μl cDNA, 12.5 μl 2X PCR master mix (Promega, Madison, WI), 10
μM forward and reverse primers, 0.25 μl 100X SYBR Green I (Invitrogen, Carlsbad,
CA). Primer pairs targeting genes of interest were designed using Lasergene
software (DNAstar, Madison, WI). Primer pairs were designed for target gene cyclin
D1 and reference gene 18S for mRNA amplification. Product amplification was
quantified using the iCycler iQ Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules, CA). To determine the linear range of amplification and to
account for primer efficiency of each primer set, quantification values were
calculated based on a standard curve constructed from a dilution series (125).
Each experimental condition was tested in triplicate. The mean of the triplicate
samples target gene were normalized to the mean of triplicate 18S values from the
same sample set. Results were expressed as a ratio of the relative expression of
treated samples to control samples +/- SEM. Specificity of each primer set for one
product was verified by the formation a single melting peak and by agarose gel
electrophoresis.
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Quantification of Protein Synthesis
Selected cell lines were plated in 96-well plates so that the confluency of
cells in the control wells reached approximately 60-70% at the conclusion of the
experiment. Cells were allowed to adhere over 24 hours. 3-6 hours prior to
experiment start, media was replaced with fresh warmed media to minimize
metabolic stress from media consumption. Cells were then incubated for 4 hours
with DMSO, 0.5 μg/ml tunicamycin, or 10 nM thapsigargin. After treatment, cells
were gently washed with PBS once and then pulse-labeled in leucine-free media
(MP Biomedicals, Solon, OH) with 2 μCi/ml L-[4,5-3H] leucine (PerkinElmer,
Waltham, MA) for 2 hours in an incubator at 37ºC and 5% CO2. Cycloheximide (50
μM) was included as a positive control for protein synthesis inhibition and was coincubated with tritiated leucine during the 2 hour incubation. Non-incorporated L[4,5-3H] leucine was removed by gently washing cells in ice-cold phosphatebuffered saline once. Cells were then lysed in 100 μl of 0.1 M KOH and harvested
onto fiberglass filters using a plate harvester. Incorporated tritiated leucine into
proteins was quantified using a scintillation counter.

Measurement of Cyclin D1 Degradation
Degradation of cyclin D1 was assessed in non-tumorigenic cell line HPDE
and human pancreatic cancer cell line Hs766T. Cell lines were incubated in
tunicamycin (0.5 μg/ml), cycloheximide (50 μM), or tunicamycin (0.5 μg/ml) with
cycloheximide (50 μM) and collected at 10-minute intervals up to 60 minutes.
Cyclin D1 protein was immunoblotted and bands quantified as described above.
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Cyclin D1 levels were normalized to β-actin levels. The slopes of the time courses
were calculated and compared using the GraphPad Prism 5.03 statistical software
(GraphPad Software, San Diego, CA). The equations for the slopes were used to
calculate the half-lives, t1/2, of cyclin D1.

[6-3H]-Thymidine Incorporation Assays
Wild-type and S51A mouse embryonic fibroblasts (MEFs) were plated in 96well plates so that the confluency of cells in the DMSO-treated control wells reached
approximately 70-80% at the conclusion of the experiment. Cells were allowed to
adhere for at least 24 hours. 3-6 hours prior to experiment start, media was
replaced with fresh warmed media to minimize metabolic stress from media
consumption. Cells were exposed to DMSO or 0.5 μg/ml tunicamycin for 4 hours.
After treatment, cells were gently washed with PBS once and then pulse-labeled
with 10 μCi/ml [6-3H] thymidine (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ) for 1 hour at 37ºC under normoxic conditions in an incubator. Nonincorporated [6-3H] thymidine was removed by gently washing cells with PBS once.
Cells were then lysed in 100 μl of 0.1 M KOH and harvested onto fiberglass filters
using a plate harvester. Incorporated tritiated thymidine was quantified using a
scintillation counter.
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Statistical Analysis
Unless otherwise specified, experiments represented in figures represent of
at least three independent experiments. Statistical analyses were conducted with
the GraphPad Prism 5.03 statistical software (GraphPad Software, San Diego, CA).
Statistically significant differences between two groups were determined using the
two-tailed unpaired Student’s t test. For three or more groups, comparison by twoway ANOVA was performed followed by a Bonferroni’s post-test analysis.
Statistical significance was determined as p < 0.05 in all cases.
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RESULTS
PANCREATIC CANCER CELLS HAVE IMPAIRED CELL CYCLE INHIBITION
AFTER TUNICAMYCIN TREATMENT
In Figure 4 from Chapter Two, I established that on-tumorigenic pancreatic
ductal cells were more sensitive to inhibition of DNA synthesis after ER stress than
pancreatic cancer cell lines. This response was in compared to the impaired ability
of pancreatic cancer cells to inhibit DNA synthesis at the same respective doses.
Since DNA synthesis measures proliferation of viable cells, we also established in
Chapter Two that the inhibition of DNA synthesis in non-tumorigenic cells was not
due to a loss of cells to apoptosis. Since differences in DNA synthesis and nontumorigenic and pancreatic cancer cells could not be attributed to apoptosis, we
next assessed whether this difference could be the result of differences in cell cycle
status.

Non-tumorigenic pancreatic ductal cells undergo G1 phase arrest.
I examined whether the decrease in DNA synthesis correlated with induction
of cell cycle arrest. I performed cell cycle analysis using propidium iodide staining
followed by flow cytometry to determine whether non-tumorigenic cells underwent
cell cycle arrest after ER stress. In non-tumorigenic pancreatic ductal cells,
treatment with tunicamycin resulted in a time-dependent reduction of cells in Sphase coinciding with an increased percentage of cells entering G0/G1 phase arrest
(Figure 11 and Figure 12).
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Figure 11. Treatment with tunicamycin induced a G1 phase arrest in
non-tumorigenic cell line HPDE. HPDE cells were treated for 0 or 20 hours
with DMSO or tunicamycin (0.5 μg/ml). Cell cycle analysis demonstrated an
accumulation of cells in G0/G1 and a decreased percentage of cells in Sphase after incubation with tunicamycin. Similar results were obtained in at
least 3 separate experiments.
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Figure 12. Non-tumorigenic cell lines demonstrate a time-dependent decrease
of cells in S-phase with a proportionate increase of cells in G0/G1 phase.
Representative data from cell cycle analysis by flow cytometry using propidium iodide
staining is shown. Non-tumorigenic pancreatic ductal cells HPDE, A, and HPNE, B,
were treated with tunicamycin (0.5 µg/ml) over a 24-hour time course. The DMSOtreated control was treated for 24 hours. Experiments were performed in two
independent experiments with similar results.
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Inhibition of cell cycle progression is reduced in pancreatic cancer cells.
To determine whether the differences between in DNA synthesis observed in
Figure 4 between non-tumorigenic and pancreatic cancer cells, we next performed
cycle analysis on pancreatic cancer cell lines. In comparison to non-tumorigenic
cells, pancreatic cancer cells demonstrated an increased percentage of cells in Sphase following tunicamycin treatment (Figure 13). For the purposes of comparing
across cell lines with different starting fractions of cells in S-phase, the percentages
of cells in S-phase in the tunicamycin-treated samples were normalized to those of
their respective DMSO-treated controls. Pancreatic cancer cell lines exhibited a
statistically significant (p<0.05) inability to inhibit progression to S-phase compared
to non-tumorigenic cells.
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Figure 13. Pancreatic cancer cells have an increased proportion of cells in Sphase after tunicamycin treatment. S-phase results from cell cycle analysis by flow
cytometry using propidium iodide staining. Non-tumorigenic pancreatic ductal cells (in
pink hues, HPDE, HPNE) and pancreatic cancer cells (in blue hues, Pa-Tu-8902,
HPAC, AsPC-1) were treated with vehicle DMSO or tunicamycin (TU, 0.5 μg/ml) for 24
hours. Human pancreatic cancer cells displayed a decreased ability to inhibit
progression to S-phase compared to non-tumorigenic cell lines. Percentages of cells
in S-phase were normalized to their respective DMSO-treated controls. Statistical
analysis performed by 2-way ANOVA. Columns, n=3; error bars represent SEM. *,
p<0.05 as compared to HPDE with respective treatment, ‡, p<0.05, as compared to
HPNE, with respective treatment.

78

Tunicamycin causes cyclin D1 loss in non-tumorigenic cell lines
Since we observed that non-tumorigenic pancreatic cells successfully
entered G1 phase arrest, we next examined cyclin D1. We considered cyclin D1
the most reasonable target given its critical role as a key regulator of the G1 to Sphase transition. Additionally, previous studies by the Diehl laboratory have
established that the UPR plays a regulatory role in cyclin D1 translation (85, 86).
Treatment with tunicamycin (0.5 μg/ml) for 4 hours with comparison to
DMSO-treated controls demonstrated that non-tumorigenic cells effectively
downregulated cyclin D1 levels to 34 +/- 3% and 41 +/- 2% of remaining protein in
HPDE and HPNE cells, respectively. These results indicate non-tumorigenic cells
repressed cyclin D1 expression by >50% compared to their DMSO-treated controls.
These results were consistent with the involvement of cyclin D1 in mediating G0/G1
phase arrest in non-tumorigenic cells.
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Figure 14. Tunicamycin inhibits cyclin D1 protein levels in nontumorigenic pancreatic ductal cell lines. HPDE and HPNE cells were
exposed to DMSO (D) or 0.5 μg/mL tunicamycin (Tu) for 4 hours. A,
Representative immunoblots of similar data are shown. B, Cyclin D1
protein levels were measured by immunoblotting and quantified using
Odyssey software. Columns represent n = 3, error bars represent
standard error of the mean (SEM).
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Tunicamycin fails to downregulate cyclin D1 protein levels in a screen of
pancreatic cancer cell lines
Given that previous experiments showed non-tumorigenic pancreatic cells
were capable of inducing G0/G1 phase arrest that correlated with a decrease in
cyclin D1 levels following tunicamycin treatment, we next examined whether
pancreatic cancer cells were capable of downregulating cyclin D1 protein levels.
Non-tumorigenic pancreatic cell lines HPDE and HPNE were used as comparison
cell lines that most closely resemble normal pancreatic ductal cells. In these nontumorigenic pancreatic cell lines, cyclin D1 expression was consistently
downregulated levels to <50% of their DMSO-treated controls (Figure 14). This was
consistent with experiments in wild-type mouse embryonic fibroblasts (MEFs),
which also decreased cyclin D1 to <50% of baseline values (discussed later).
In an initial screen of 22 pancreatic cancer cell lines demonstrated that 15
out of 22 (68%) cell lines were unable to inhibit cyclin D1 levels by >50% of their
DMSO-treated controls (Figure 16). Nearly half (10 of 22) of the screened cancer
cell lines had further difficulty inhibiting cyclin D1, repressing expression by <25% of
their DMSO-treated controls. For the purposes of this study, we defined ER stressresponsive cells as cell lines which downregulated cyclin D1 by >50% of their
baseline values. Cell lines that downregulated cyclin D1 by <50% were designated
as “resistant” to ER stress-mediated downregulation. Although a majority of cell
lines demonstrated an impaired ability to downregulate cyclin D1 in our initial screen
of 22 pancreatic cancer cells lines, the degree of impairment of cyclin D1 was highly
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variable. This variability is not an unexpected finding given the marked
heterogeneity among pancreatic tumors (34).
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Figure 15. Screen of pancreatic cancer cell lines suggests impaired
inhibition of cyclin D1 protein expression. Pancreatic cell lines were treated
with DMSO or 0.5 μg/ml tunicamycin for 4 hours. Quantification results from
immunoblots for cyclin D1 normalized to β-actin. All cell lines have been
represented as a percentage of their cyclin D1/β-actin expression compared to
their respective DMSO-treated controls. Black columns represent nontumorigenic pancreatic ductal cell lines; gray columns represent pancreatic
cancer cell lines. Red line indicates distinction at 50% marker indicating
“resistance” to ER stress-mediated downregulation of cyclin D1. Columns with
error bars represent mean (n=3); bars represent standard error of the mean
(SEM). Columns with no error bars represent screened cell lines where
immunoblot was performed only once.
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Tunicamycin has impaired repression of cyclin D1 levels in pancreatic cancer
cell lines
To confirm the results of the initial screen, three of the pancreatic cancer cell
lines that were least able to downregulate cyclin D1 were selected for further
studies: Pa-Tu-8902, HPAC, and AsPC-1.

Time courses over 24 hours

demonstrated an impaired cyclin D1 repression in pancreatic cancer cell lines
compared to non-tumorigenic cell lines after exposure to tunicamycin (Figure 16).
In non-tumorigenic cells, cyclin D1 reduction by >50% occurred within 4 hours of
tunicamycin exposure. Over the same exposure times of tunicamycin treatment,
the proportion of cyclin D1 lost from baseline in cancer cell lines was dramatically
deficient compared to non-tumorigenic cell lines. While non-tumorigenic cells were
capable of downregulating cyclin D1 levels to <30% of baseline in HPDE cells and
<10% of baseline in HPNE cells by the end of the 24-hour tunicamycin exposure,
pancreatic cancer cells were unable to reduce cyclin D1 levels to below 50% over
the entire 24 hours Figure 16). In comparison, non-tumorigenic pancreatic ductal
cells reduce cyclin D1 levels to <50% in less than 4 hours. All experiments were
performed at least twice with similar trends in expression.
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Figure 16. Time-dependent effects of tunicamycin on cyclin D1 protein. Nontumorigenic pancreatic cell ductal cell lines (A, HPDE and HPNE) and pancreatic
cancer cell lines (B, next page, Pa-Tu-8902, AsPC-1, and HPAC) were exposed to
tunicamycin (0.5 μg/ml) for durations of 0, 4, 8, 12, 18, and 24 hours. The DMSOtreated vehicle control, “D”, for each cell line was treated for 24 hours. Cyclin D1
levels were measured by immunoblotting. All experiments were repeated at least
twice with similar results obtained.
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Figure 17. Pancreatic tumor cells have diminished cyclin D1 repression
after tunicamycin. Graphical comparison of cyclin D1 levels after timedependent tunicamycin treatment in pancreatic cancer cell and nontumorigenic pancreatic ductal cells. Pancreatic cancer cell lines (AsPC-1, PaTu-8902, and HPAC) and non-tumorigenic cells were exposed to tunicamycin
(0.5 μg/ml) for 4 hours. 40 μg of whole cell lysate was loaded onto SDSPAGE gels, transferred, and immunoblots quantified by Odyssey software.
Values were normalized to β-actin as an internal loading control and
represented as a percentage of the 0-hr time point. All time courses were
repeated in at least two separate experiments with similar results. Curves are
the representative results of data quantified from immunoblots of time courses
for each cell line.
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Pancreatic cancer cells do not decrease phosphorylation status of
retinoblastoma protein as effectively in response to tunicamycin
To further confirm that non-tumorigenic pancreatic cells were undergoing cell
cycle arrest via cyclin D1 downregulation, the phosphorylation status of
retinoblastoma (Rb) protein was evaluated. Cyclin D1 is a key regulator of the G1-S
phase checkpoint through assembly of a complex with cyclin-dependent kinase-4
(CDK4) and cyclin-dependent kinase-6 (CDK6). Cyclin D1 subsequently causes
phosphorylation of Rb protein. Hyperphosphorylation of Rb protein results in its
release of E2F transcription factors, which results in the transcription of genes
responsible for promoting the G1 to S-phase transition and continued cell cycle
progression. Hypophosphorylation of Rb protein, therefore, results in continued
binding to E2F with cell cycle arrest at the G1 to S-phase transition.
Since non-tumorigenic cell lines entered G0/G1 phase arrest with an
associated decrease in cyclin D1, we expected a decrease in Rb phosphorylation
status of our non-tumorigenic cell lines. Conversely, we predicted pancreatic
cancer cell lines should have decreased loss of Rb phosphorylation. As expected,
in our non-tumorigenic cell line HPNE, tunicamycin caused complete loss of Rb
phosphorylation by 18 hours of treatment. In contrast, phosphorylation of Rb
persisted even until 24 hours in pancreatic cancer cell lines Pa-Tu-8902 and HPAC.
Loss of phosphorylation occurred earlier and to a greater degree in non-tumorigenic
cell line HPNE than pancreatic cancer cell lines. These results are consistent with
prior cell cycle analysis experiments demonstrating induction of G1 cell cycle arrest
in non-tumorigenic cells but block or delayed arrest in pancreatic cancer cell lines.
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A)

Figure 18. Phosphorylation status of retinoblastoma protein correlates
with cell cycle arrest. Immunoblots of phospho-Rb following tunicamycin
exposure (0.5 μg/ml) over 24 hour time course. A, Non-tumorigenic pancreatic
cell ductal cell line HPNE exhibits complete loss of phosphorylation of
retinoblastoma protein by 18 hours of tunicamycin exposure. B (next page),
pancreatic cancer cell lines (Pa-Tu-8902, AsPC-1, and HPAC) display
phosphorylation of retinoblastoma protein through the entire 24 hour time
course. The DMSO-treated vehicle control, “D”, for each cell line was treated
for 24 hours. All experiments were repeated at least twice with similar results
obtained. Representative immunoblots are shown of similar data.
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DECREASED CYCLIN D1 LOSS IN PANCREATIC CANCER CELLS IS DUE TO
IMPAIRED INHIBITION OF TRANSLATION
Regulation of cyclin D1 occurs at multiple levels including transcription,
translation, and degradation. To determine the cause for differences in cyclin D1
protein expression between non-tumorigenic and pancreatic cancer cell lines, I
examined the various levels cyclin D1 protein regulation to identify the principal
mechanism for differences in cyclin D1 levels.

Early loss of cyclin D1 protein is not attributed to loss of cyclin D1 mRNA.
Since a reduction in cyclin d1 levels in non-tumorigenic cells could also be a
reflection of decreased messenger RNA levels, I determined through quantitative
polymerase chain reaction (Q-PCR) whether cyclin D1 mRNA levels were affected
by treatment with tunicamycin.
I previously showed that cyclin D1 loss to <50% of the initial protein level in
non-tumorigenic cells occurs within 4 hours of tunicamycin exposure (Figure 16).
Q-PCR results demonstrate that reduction in cyclin D1 mRNA levels in all cell lines
did not occur until after the initial loss of cyclin D1 protein observed at 4 hours.
While cyclin D1 mRNA levels were shown to diminish over the entire 24-hour time
course in non-tumorigenic pancreatic ductal cells, a significant reduction of its
message did not occur until at least 8 hours of treatment in HPDE cells and 12
hours in HPNE cells. These results were consistent across repetitions. These
observations were also noted previously in NIH-3T3 cells where a cyclin D1 mRNA
loss was also not observed until 8 hours (86). Interestingly, pancreatic cancer cells

91

demonstrated a reduced ability to reduce cyclin D1 mRNA by 24 hours. Parallel
treatment of cell lines with DMSO-treated control for 24 hours indicated that the
reduction in cyclin D1 mRNA levels in HPNE cells was not due to a growth inhibition
from increased confluency. In pancreatic cancer cell lines, the DMSO-treated
control never demonstrated more inhibition of cyclin D1 mRNA than the 24-hour
tunicamycin-treated sample. This indicates that any inhibition of cyclin D1 mRNA
levels reflected an effect of tunicamycin treatment rather than vehicle or confluency.
In the representative experiment for AsPC-1 cells in Figure 19, the DMSO-treated
control showed cyclin D1 mRNA levels (61 +/- SD 6%) that were statistically
equivalent to the 24-hour tunicamycin-treated sample (61% +/- SD 9%). This
indicates that the downregulated cyclin D1 mRNA effect observed in AsPC-1 was a
result of confluency and not of treatment. Repetitions of the time course showed
that AsPC-1 cyclin D1 mRNA levels at 24 hours were always either statistically
equivalent or above the DMSO-treated control. The results are consistent with an
impaired ability of AsPC-1 to downregulate cyclin D1 mRNA. Of note, Q-PCR
experiments with HPDE cells did not include a DMSO-treated control, but cell cycle
analysis of HPDE cells consistently demonstrated that cell cycle was unaffected by
treatment with DMSO while tunicamycin treatment caused cell cycle arrest (Figure
11 and Figure 12).
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Figure 19. Loss of cyclin D1 mRNA occurs after cyclin D1 protein levels
decline. Quantitative polymerase chain reaction was used to measure levels of
cyclin D1 mRNA in respective cell lines at 0, 4, 8, 12, and 24 hours of treatment
with tunicamycin (0.5 µg/ml). Cyclin D1 loss does not begin to decline until at
least 8 hours in both non-tumorigenic or pancreatic cancer cell lines.
Representative results are shown. Similar results were obtained from at least 2
different repetitions. Error bars represent standard deviation (SD).
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Pancreatic cancer cells have diminished ability to attenuate translation in
pancreatic cancer cells.
To determine the mechanism for a reduced capacity to reduce cyclin D1
protein levels, I next tested whether pancreatic cancer cells had diminished capacity
to reduce cyclin D1 levels due to differences in translation. Since the PERK/eIF2α
pathway is a well-established regulator of global protein synthesis, differences in
cyclin D1 protein levels seemed most likely to involve this pathway. Additionally,
ER stress has previously been established as a potent inhibitor of cyclin D1
translation through the UPR’s PERK/eIF2α pathway (86). Since tunicamycin and
thapsigargin are classic inducers of ER stress, I examined the inhibitory effects of
tunicamycin and thapsigargin on the synthesis of new proteins through biosynthetic
labeling with L-[4,5-3H]-leucine. Pancreatic cancer cells exhibited a marked
ineffectiveness in inhibiting protein synthesis (Figure 20). Pancreatic cancer cells
could reduce L-[4,5-3H]-leucine incorporation by no greater than 12% of their
DMSO-treated controls. In contrast, non-tumorigenic pancreatic ductal cells were
able to reduce protein synthesis at least by 39% of their respective DMSO-treated
controls (p<0.001). These findings indicate that pancreatic cancer cells possess a
clear dysregulation in inhibiting translation in response to ER stress. The
decreased ability to suppress translation was consistent across two ER stressors
with different mechanisms of disturbing protein folding provides support that this
deficiency in regulation of translation applies to ER stress in general, not specific
drugs.
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The finding that translation is not inhibited in pancreatic cancer cells is
consistent with our phospho-eIF2α data in Chapter Two. I showed previously that
pancreatic cancer cells had an increased time of onset as well as a decreased
magnitude of eIF2α phosphorylation. My data demonstrating that pancreatic cancer
cells possess a delayed ability to phosphorylate eIF2α correlates well with this
chapter’s results delineating impaired cyclin D1 downregulation and a deficient
translational inhibition in response to ER stress.
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Figure 20. Pancreatic cancer cells demonstrate diminished ability to
attenuate translation. Non-tumorigenic pancreatic ductal cell lines and
pancreatic cancer cell lines were treated for 4 hours with DMSO,
tunicamycin (TU, 0.5 µg/ml), or thapsigargin (TG, 10 nM) in ideal media.
Cells were then pulsed with L-[4,5-3H]-leucine for 2 hours in leucine-free
media. Cycloheximide (CHX, 50 µM) was included as a positive control
for protein synthesis inhibition. Values represent the percentage of L-[4,53H]-leucine incorporated compared to the DMSO-treated control. *,
p<0.001, as compared to HPDE; ‡, p<0.001, as compared to HPNE.
Comparisons are made between treatments of tunicamycin or
thapsigargin. All experiments were performed in at least three
independent experiments.
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Phosphorylation of cyclin D1 degradation regulator GSK3β does not correlate
with expression of cyclin D1.
The third possible explanation for a reduced ability to downregulate cyclin D1
in pancreatic cancer cells is an increased accumulation of cyclin D1 protein due to
decreased degradation. To determine whether delayed repression of cyclin D1 was
caused by decreased degradation, phosphorylation status of glycogen synthase
kinase-3β (GSK3β) was evaluated. Phosphorylation of cyclin D1 at threonine 286
by the GSK3β facilitates degradation of cyclin D1 and its redistribution from the
nucleus to the cytoplasm. Cyclin D1 proteolysis occurs through ubiquitination and
degradation by the 26S subunit of the proteasome.
GSK3β is regulated through phosphorylation which results in its inactivation.
Subsequently, upregulated GSK3β phosphorylation results in inhibited cyclin D1
degradation and an increase in cyclin D1 protein. Since pancreatic cancer cells
have decreased repression of cyclin D1 levels, an increase in the phosphorylation
of GSK3β would be expected. However, no change in phosphorylation status of
GSK3β occurred through the time course in either pancreatic cancer cells or nontumorigenic cells (Figure 21). These data indicate that GSK3β is not involved in
cyclin D1 protein levels.
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Figure 21. Phosphorylation of glycogen synthase kinase-3β does not
correlate with cyclin D1 loss. Immunoblot of phospho-GSK3β following
tunicamycin exposure (0.5 μg/ml) over 24 hour time course. Non-tumorigenic
pancreatic cell ductal cell lines (A, HPDE and HPNE) and pancreatic cancer
cells lines (B, next page, Pa-Tu-8902, AsPC-1, and HPAC) do not change
phosphorylation status of GSK3β in response to tunicamycin. The DMSOtreated vehicle control, “D”, for each cell line was treated for 24 hours. All
experiments were repeated at least twice with similar results obtained.
Representative blot of similar data is shown.
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Cyclin D1 degradation is not responsible for decreased downregulation of
cyclin D1 in pancreatic cancer cells.
Since cyclin D1 degradation has also been shown to be regulated by
molecules other than GSK3β, such as p38SAPK2 and Skp- Cullin- F-box (SCF)
complexes, I also analyzed general cyclin D1 degradation rates. The protein
synthesis inhibitor cycloheximide (CHX) was utilized as a tool to examine the halflife, t1/2, of cyclin D1. The average t1/2 for cyclin D1 was previously reported to be
only ~25 minutes in NIH-3T3 cells (86).
If impaired loss of cyclin D1 in pancreatic cancer cell lines were due to an
accumulation of cyclin D1, I would expect to see decreased degradation of cyclin
D1 and an increased t1/2. Examination of degradation rates of cyclin D1 over 60
minutes demonstrated a comparable t1/2 of cyclin D1 at ~26 minutes with CHX alone
and ~28 minutes with combined tunicamycin and cycloheximide treatment. This
was not substantially different compared to a t1/2 of ~24 minutes when treating
pancreatic cancer cell line Hs766T with combined tunicamycin and cycloheximide
treatment. Unexpectedly, Hs766T actually consistently trended toward a higher t1/2
of cyclin D1 at ~31 minutes when treated with CHX alone. These results suggest
that the initial turnover rate of cyclin D1 is slightly slower at a t1/2 of 31 minutes,
tunicamycin actually promotes rather than inhibits degradation of cyclin D1 to a t1/2
of 24 minutes in the pancreatic cancer cell line. My findings provide strong
evidence that impaired cyclin D1 downregulation in this pancreatic cancer cell line
was not due to increased accumulation of cyclin D1.
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Figure 22. Cyclin D1 degradation is not inhibited in pancreatic
cancer cell lines. Cyclin D1 protein levels were quantified on
immunoblots of tumorigenic cell line HPDE, A, and human pancreatic
cancer cell line, Hs766T B. Cell lines were treated with tunicamycin (Tu,
0.5 µg/ml), cycloheximide (CHX, 50 µM), or combination tunicamycin (0.5
µg/ml) with cycloheximide (50 µM) in a time course of increments of 10
minutes up to 60 minutes. Slopes were not significantly different between
combination Tu+CHX or CHX alone in either cell line.
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Expression of p27Kip1 does not correlate with cell cycle arrest
Expression of cyclin-dependent kinase inhibitor p27Kip1 in non-tumorigenic
cell line HPNE demonstrates brief downregulation until 12 hours of tunicamycin
treatment before a rapid increase in p27Kip1. Overexpression of p27Kip1 should
induce cell senescence. However, p27Kip1 expression is also induced in pancreatic
cancer cell lines within 2 hours of treatment without any induction of cell cycle
arrest. This indicates that expression of p27Kip1 does not correlate with induction in
non-tumorigenic cells or failed induction of cell cycle arrest in pancreatic cancer
cells.

102

A)

Figure 23. p27Kip1 expression does not correlate with cell cycle arrest.
Immunoblot of p27Kip1 following tunicamycin exposure (0.5 μg/ml) over 24
hour time course. A, non-tumorigenic pancreatic cell ductal cell line HPNE
exhibits initial decline of p27Kip1 until 18 hours before rapidly increasing until
24 hours. B (next page), pancreatic cancer cell lines (Pa-Tu-8902, AsPC-1,
and HPAC) display an initial increase of p27Kip1 expression as early as 2
hours. The DMSO-treated vehicle control, “D”, for each cell line was treated
for 24 hours. All experiments were repeated at least twice with similar results
obtained.
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CONTROL OF CELL CYCLE ARREST DEPENDS ON EIF2α
PHOSPHORYLATION IN MUTANT MOUSE EMBRYONIC FIBROBLAST
SYSTEM
To determine whether the eIF2α pathway could be a possible mechanism for
the defective translational attenuation, I examined whether eIF2α phosphorylation
was required to inhibit translation by utilizing a mutant mouse embryonic fibroblast
(MEF) model system. In this mutant model MEF system, the phosphorylation site of
eIF2α at Ser51 was mutated to an Ala51 (S51A MEFs). Mutation of this site
prevents the phosphorylation of eIF2α and subsequently inhibits GDP to GTP
exchange by eIF2B, effectively preventing global inhibition of protein synthesis.

Failure to phosphorylate eIF2α leads to an inability to attenuate translation in
mouse embryonic fibroblasts (MEFs).
To illustrate that translational inhibition was dependent on eIF2α
phosphorylation, I compared S51A and WT MEFs ability to incorporate L-[4,5-3H]leucine as a measure of protein synthesis. WT MEFs inhibited incorporation of L[4,5-3H]-leucine to 59.0% +/- 5.3% with tunicamycin and 51.8% +/- 2.5% with
thapsigargin from their baseline values. In contrast, S51A MEFs demonstrated a
complete inability of S51A MEFs to inhibit translation. These findings recapitulated
previously published experiments using these phosphorylation-deficient MEFs (86).
This findings are comparable to the deficient translational inhibition observed in
pancreatic cancer cells (Figure 20) and provide evidence that abrogated
translational inhibition was mediated through eIF2α phosphorylation.
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Figure 24. Phosphorylation-deficient MEFs demonstrate diminished ability
to attenuate translation. WT and S51A MEFs were treated for 4 hours with
DMSO, tunicamycin (TM), or thapsigargin (TG) in ideal media. Cells were then
pulsed with L-[4,5-3H]-leucine for 2 hours in leucine-free media.
Phosphorylation-deficient S51A MEFs were completely unable to abrogate
protein synthesis compared to WT MEFs, which showed strong translational
inhibition after ER stress induction. Cycloheximide (CHX) was included as a
positive control for protein synthesis inhibition. Values represent the
percentage of L-[4,5-3H]-leucine incorporated compared to the DMSO-treated
control. *, p<0.001, as compared to WT MEFs according to respective
treatments of tunicamycin or thapsigargin. Columns, n=3, error bars represent
SEM.
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Cyclin D1 loss is dependent on eIF2α in a S51A mutant mouse embryonic
fibroblast model system.
Since our MEF model system demonstrated that translational attenuation
was shown to be controlled through eIF2α, we next examined whether cyclin D1
repression was also deficient in our S51A MEFs. If our hypothesis were correct that
cyclin D1 loss were dependent on eIF2α-mediated translational inhibition, we
predicted that S51A MEFs would be unable to downregulate cyclin D1, similarly to
pancreatic cancer cell lines. Expression of cyclin D1 protein after tunicamycin (0.5
μg/ml) treatment in S51A MEF cells was compared to wild-type (WT) MEF cells.
WT MEFs were able to cause cyclin D1 loss to 52 +/- 5% of DMSO-treated levels.
S51A MEFs, in contrast, were completely unable to repress cyclin D1 levels
(p<0.05), which was consistent with our expectations and previous studies that
demonstrated cyclin D1 loss was mediated through eIF2α phosphorylation. These
findings provide further support that the reduced ability to inhibit cyclin D1 in
pancreatic cancer cells is dependent on eIF2α phosphorylation.
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A)

B)

Figure 25. Phosphorylation-deficient MEFs are unable to
downregulate cyclin D1 levels. Wild-type and phosphorylation-deficient
S51A MEFs were exposed to DMSO (D) or 0.5 μg/ml tunicamycin (Tu) for
4 hours. A, Representative immunoblot of cyclin D1 levels in wild-type
(WT) and phosphorylation-deficient MEFs (S51A). B, Cyclin D1 levels
were measured by immunoblotting and normalized to β-actin levels. The
results of three independent experiments were quantified, *, p<0.05.
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Inhibition of DNA synthesis is dependent on eIF2α in S51A mutant mouse
embryonic fibroblast (MEF) model system.
Since cyclin D1 repression was demonstrated to be deficient in S51A MEFs,
we next determined whether DNA synthesis was also dependent on eIF2α
phosphorylation. Inhibition of DNA synthesis was considered an indirect measure
of reduced proliferation and therefore, cell cycle arrest. Since we previously
demonstrated that cyclin D1 loss was dependent on eIF2α phosphorylation, we
predicted that DNA synthesis would be fail to be inhibited. As predicted, S51A
MEFs were unable to inhibit DNA synthesis in a dose-dependent manner. While
S51A MEFs exhibited a slightly positive slope, WT MEFs demonstrated a steeply
negative slope indicating prominent inhibition of DNA synthesis with increasing
tunicamycin concentrations. These results are consistent with my studies in
pancreatic cancer where both DNA synthesis and G0/G1 cell cycle arrest had
reduced inhibition.
Through these experiments in the mutant model MEF system examining
translation, cyclin D1 loss, and DNA synthesis inhibition, I provide strong support
that the reduced ability of pancreatic cancer cells to repress cyclin D1 and undergo
cell cycle arrest is mediated through reduced eIF2α phosphorylation.
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[H3] Thymidine Uptake
(Compared to DMSO Control)

WT MEFs
S51A MEFs
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Figure 26. Tunicamycin is less effective in inhibiting DNA synthesis
in phosphorylation-deficient S51A MEFs compared to wildtype
MEFs. Wildtype and S51A MEFs were exposed to increasing
concentrations of tunicamycin (DMSO-treated control, 0.016, 0.08, 0.4, 2,
and 10 μg/ml. S51A MEFs clearly demonstrate an inability to inhibit DNA
synthesis with increasing concentrations of tunicamycin. This is in
contrast to WT MEFs which exhibit a dose-dependent inhibition of DNA
synthesis. Slopes were calculated for each dose-dependent curve, *,
p<0.05. Results were obtained from two independent experiments.
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DISCUSSION
In Chapter Two, we discovered that pancreatic cancer cells possessed an
altered unfolded protein response to ER stress induction. Phosphorylation of the
eIF2α and activation of the IRE1α/XBP1s pathways were delayed in comparison to
non-tumorigenic cells. We also made the observation that pancreatic cancer cells
also required higher concentrations of tunicamycin to inhibit DNA synthesis (). We
aimed to determine whether the altered UPR observed in Chapter Two also
impacted cell cycle regulation. This study makes a novel discovery demonstrating
that a subset of pancreatic cancer cells has a diminished ability to downregulate
cyclin D1 in response to ER stress induction. This dysregulation was dependent on
translational control of cyclin D1 through delayed activation of the PERK/eIF2α arm
of the UPR.
Cell cycle analysis comparing non-tumorigenic pancreatic ductal cells to
pancreatic cancer cell lines indicated a decreased ability in pancreatic cancer cells
to enter cell cycle arrest after treatment with tunicamycin. Cell cycle exit occurred in
the G1 to S phase transition in non-tumorigenic cells while pancreatic cancer cells
demonstrated a statistically significant increased percentage of cells entering S
phase. Consistent with cell cycle arrest in G1 phase, HPNE cells exhibited loss of
phosphorylation of retinoblastoma protein while continued cycle progression
correlated with retention of Rb phosphorylation in pancreatic cancer cells.
Examination of cyclin D1 as a possible regulatory target of the UPR was chosen
given its critical role in mediating the G1 to S phase transition. Additionally, in NIH3T3 and mouse embryonic fibroblasts, the PERK arm of the UPR has been
111

documented to regulate cyclin D1 translation and cause G1 cell cycle arrest (85, 86,
126).
Cyclin D1 is a well-known driver of cell cycle progression critical to the
pathogenesis of many types of cancer. It is frequently overexpressed in different
types of cancer and has also been heavily implicated as a mechanism of
chemoresistance, particularly in pancreatic cancer (78, 79, 82-84, 127, 128). Cyclin
D1 levels are closely regulated through mitogenic signaling inputs, such as through
the Ras/Raf/MAPK pathway. Persistent mitogenic signaling is required for active
cyclin D1/CDK4 complexes. In normal cells, withdrawal of growth factors results in
decreased Ras signaling and rapid turnover of cyclin D1. Regulation of this process
enables cells to quickly adjust to growth requirements to changes in the
extracellular environment.

In pancreatic adenocarcinomas, oncogenic KRAS is

mutated in >90% of cases and likely makes a significant contribution to driving
cyclin D1 expression (129, 130). The increased proliferative demand created by
KRAS, cyclin D1, and other growth-promoting factors leads to increased tumor
growth which outstrips the vascular supply.

The limited availability of hypoxia,

nutrients, and glucose creates a tumor microenvironment predisposed to induction
of ER stress.

The conundrum remains that if conditions in the tumor should

promote ER stress, activation of the UPR should lead to an inhibition of cyclin D1
translation. Hypothetically, if a low level of ER stress were present, cells should
enter a state of tumor dormancy with the reduction of cyclin D1. However, given the
hypovascularity, increased proliferative demand, and chemoresistant character of

112

pancreatic adenocarcinomas, these tumors likely possess an adaptive stress
response to counter the increased hypoxic and metabolic demands.
Our studies indicate that a subset of pancreatic cancer cells exhibit a
decreased ability to downregulate cyclin D1 compared to non-tumorigenic cell lines.
Both non-tumorigenic pancreatic ductal cell lines, HPDE and HPNE, and WT MEFs
exhibited abrogation of cyclin D1 levels to <50% of baseline values by 4 hours. I
demonstrate that a majority (15/22) of pancreatic cancer cells exhibited an altered
cyclin D1 downregulation in response to tunicamycin treatment. In the 24-hour time
course evaluated, pancreatic cancer cells failed to achieve a level of cyclin D1
repression.

This finding demonstrated that pancreatic cancer cells clearly

possessed a deficient cyclin D1 response to tunicamycin inhibition.

Previous

studies have also indicated that the ER stress mediates cell cycle arrest via
decreased cyclin D1 expression in A2780 (ovarian) and HT-29 (colon) cancer cell
lines (87). However, no studies have been published indicating a resistance to ER
stress-induced arrest in cancer via UPR regulation of cyclin D1.
Cyclin D1 is regulated at multiple levels, including transcription, translation,
and degradation.

While gene amplification has been shown to play a role in

mediating cyclin D1 overexpression in a number of cancers, this is not a prevalent
finding in PDAC (131). To determine the mechanism of persistence of cyclin D1 in
pancreatic cancer, we examined mRNA levels, translation, and degradation of
cyclin D1.

Our results indicate that regulation of cyclin D1 is dependent on

translational inhibition rather than at the mRNA level or protein degradation.
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Transcriptional regulation of cyclin D1 could also represent another
explanation for the reduced loss of cyclin D1 in pancreatic cancer cell lines. The
regulation of cyclin D1 transcription by mitogenic pathways, particularly the
RAS/RAF/MAPK pathway through Myc or upregulation of NFκB, is especially
important given their roles in the pathogenesis in PDAC. Our study determined that
while cyclin D1 mRNA loss eventually occurred in non-tumorigenic pancreatic cells,
this loss occurred after cyclin D1 protein reduction was observed.

This finding

indicated that the early regulation of cyclin D1 protein levels in response to
tunicamycin was not through reduced mRNA levels. However, our findings that
cyclin D1 protein loss occurred prior to mRNA reduction indicated another
mechanism dominated early cyclin D1 protein repression. This finding is consistent
with a prior study in NIH-3T3 cells that showed that cyclin D1 mRNA levels
remained unchanged after 8 hours of tunicamycin exposure while cyclin D1 protein
levels were lost after just 4 hour of treatment (86). Importantly, these results do not
discount the possibility that transcription of cyclin D1 mRNA may play a significant
role after more extended durations of tunicamycin treatment. Pancreatic cancer
cells possessed an impaired response in downregulating both mRNA and protein
levels over a prolonged treatment duration. The RAS/RAF/MAPK pathway may
indeed play a contributory role in the persistence of cyclin D1 mRNA levels over the
entire 24-hour time course.

Another explanation for the differences in the

responsiveness at the mRNA level of non-tumorigenic cells could potentially be
explained by the initial regulation of cyclin D1 at the protein level.

I hypothesize

that the early attenuation of cyclin D1 protein translation mitigates the E2F feed-
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forward response to further stimulate cyclin D1 transcription. This would result in a
compounded effect of further reducing cyclin D1 protein in non-tumorigenic cells
through transcriptional and subsequent translational processes.

In contrast, a

persistent cyclin D1 level in pancreatic cancer cells promotes further cell cycle
progression.
We

also

determined

through

degradation

experiments

that

slower

degradation of cyclin D1 was not occurring. On the contrary, it appeared that cyclin
D1 degradation was actually being promoted in the pancreatic cancer cell line
Hs766T compared to the non-tumorigenic cell line HPDE. The significance of this
finding has not been elucidated and is beyond the scope of this thesis. GSK-3β
phosphorylation, measured as an indirect measure of cyclin D1 degradation also
indicated that cyclin D1 was not accumulating in pancreatic cancer cell lines due to
decreased degradation.
Further analysis through [H3]-leucine incorporation revealed that impaired
repression of cyclin D1 was occurring through a statistically significant inability to
downregulate translation in pancreatic cancer cells (p<0.001) as compared to nontumorigenic pancreatic ductal cells. Since inhibition of translation was impaired in
pancreatic cancer cell lines, results from eIF2α phosphorylation from Chapter Two
were compared to cyclin D1 protein levels. Time-dependent expression of cyclin D1
closely correlated with phosphorylation of eIF2α and downstream effectors ATF4
and CHOP in both non-tumorigenic and pancreatic cancer cells. The relationship
between eIF2α phosphorylation and translational repression of cyclin D1 were also
confirmed with my own experiments in MEFs with eIF2α mutated at its Ser51
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phosphorylation site. Data in the MEFs recapitulated previously published work
establishing translational repression of cyclin D1 through eIF2α phosphorylation
(85, 86).
Most experiments in this study focused on tunicamycin to induce ER stress.
Admittedly, the effects observed in this study could be limited to tunicamycin’s
function as an N-linked glycosylation. Specific usage of this drug is notable since
many growth factors, such as EGFR, require N-linked glycosylation for maturation
(132, 133).

However, to circumvent the possibility that the observed cell cycle

regulatory effects are specific to tunicamycin or N-linked glycosylation, cells were
also treated with thapsigargin, a calcium ATPase inhibitor in Figure 24.

The

impaired ability to reduce [H3]-leucine incorporation was similar across nontumorigenic cells and pancreatic cancer cells after treatment with tunicamycin or
thapsigargin. Since thapsigargin functions through a mechanism distinct from
thapsigargin, the cell cycle effects are unlikely solely due to the inhibition of
glycosylation.
Cyclin D1 loss in non-tumorigenic cells correlated with previous studies
(Chapter Two) where eIF2α phosphorylation occurred prior to cyclin D1 loss.
Phosphorylation of eIF2α in pancreatic cancer cells was consistently delayed and
correlated with persistence of cyclin D1 levels as compared to non-tumorigenic
pancreatic ductal cells. The mechanism linking eIF2α phosphorylation was further
corroborated by experiments in phosphorylation-deficient mutant S51A eIF2α
MEFs. In non-tumorigenic pancreatic cells, pancreatic cancer cells, and our model
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MEF system, cyclin D1 repression consistently correlated with translational
inhibition, phosphorylation status, and stage of cell cycle progression.
The findings in this chapter underline the key observations that pancreatic
cancer cells are unable to downregulate cyclin D1 due to an impaired activation of
the eIF2α arm of the UPR. A subsequent impaired G0/G1 phase arrest occurs,
which allows continued proliferation. As mentioned in Chapter Two, UPR activation
has not been observed in pancreatic cancer with a moderate induction of ER stress
at 0.5 µg/ml tunicamycin.

Pancreatic cancer cells instead exhibit an increased

tolerance to ER stress that enables continued proliferation under conditions of
increased protein load.
These results have important clinical implications given the problem that
some chemotherapies have been noted to induce ER stress-mediated growth arrest
and apoptosis in some cancer types. However, a heightened ability to withstand the
increased protein load created by chemotherapies would allow pancreatic tumors to
be resistant to the ER stress-mediated effects. While many studies suggest that
perhaps cyclin D1 should be targeted, I suggest that cyclin D1 only represents a
readout for an underlying problem that impedes activation of the UPR in pancreatic
cancer.

Future studies identifying the mechanism that prevents UPR activation

would provide a novel target for the treatment of pancreatic cancer.
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A)

B)

Figure 27. Proposed mechanism of pancreatic cancer cell tolerance to ER
stress-mediated cell cycle arrest. In non-tumorigenic cells, A, ER stress
activates PERK. PERK phosphorylates eIF2α which inhibits protein translation and
also selectively translates ATF4 and induces CHOP expression. Inhibition of
protein translation results in decreased cyclin D1 protein levels and cell cycle
arrest/reduced proliferation. In pancreatic cancer cells, B, we propose that an
unknown mechanism prevents activation of PERK. Therefore, phosphorylation of
eIF2α is inhibited with subsequent decrease in attenuation of protein translation,
as well as delayed ATF4 and CHOP induction. Since translation is not inhibited
effectively, cyclin D1 continues to be expressed and cell cycle
progression/proliferation continues. The overall result is increased tolerance to the
growth inhibitory effects of ER stress in pancreatic cancer cells.
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CHAPTER FOUR:
SUMMARY AND FUTURE DIRECTIONS
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SUMMARY
Pancreatic adenocarcinoma is one of the deadliest cancers, ranking as the
fourth most common cause of death associated with cancer.

The disease is

extraordinarily deadly, with a an overall 5-year survival rate of only 5.6% and a
median survival of less than 6 months (4, 5). Major obstacles face advancement of
treatment options for pancreatic cancer. Current medicine lacks the ability to detect
pancreatic cancer early and the therapeutic options available provide only brief
extensions of survival.

Given the poor responsiveness of pancreatic cancer to

chemotherapy, new targets and pathways need to be investigated for potential
therapies. A key impedance to progress in treatment of pancreatic cancer is the
chemoresistance it exhibits to most chemotherapies.

Identifying methods that

sensitize chemoresistant pancreatic cancer cells is a critical component in
advancing treatment for this deadly disease.
Because of the innate ability of pancreatic adenocarcinoma to survive in the
context of hypoxia, metabolic stresses, as well as applied stresses such as through
chemotherapy, the overall goal of this dissertation was to determine whether
pancreatic cancer cells utilize adaptive mechanisms to survive in these stresses.
The hypothesis for this project was that pancreatic cancer cells have an altered
unfolded protein response to endoplasmic reticulum stress.
To test this hypothesis, I first examined whether pancreatic cancer cells
exhibited differences from non-tumorigenic cell lines in response to the classic ER
stressor tunicamycin. Pancreatic cancer cells exhibited a clear difference in their
UPR activation that permeates the PERK/eIF2α/ATF4 and IRE1α/XBP1s branches.
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Delayed induction of both of these arms of the UPR indicates that a global
mechanism upstream of ER stress activation exists.

The mechanism of how

pancreatic cancer cells avoid early activation of the UPR warrants further
investigation.

Potential explanations for this finding includes upregulated ER

chaperones that provide an increased capacity for protein load before stress
induction, increased autophagy sequestration of aberrant proteins, or factor(s) that
have yet to be identified that inhibit activation of the ER transmembrane UPR
receptors.
Additionally, this study determined that the altered unfolded response
resulted in an important impairment of cyclin D1 translational repression and cell
cycle arrest. I determined that while mRNA regulation may influence cyclin D1
protein levels over longer periods of tunicamycin treatment, the early loss of cyclin
D1 in non-tumorigenic but not pancreatic cancer cells was primarily caused by an
impaired eIF2α pathway. Delayed activation of this branch of the UPR resulted in
an impaired attenuation of protein translation. Over the same 24 hour exposure to
tunicamycin, pancreatic cancer cells were incapable of achieving the same
proportion of cyclin D1 loss as non-tumorigenic pancreatic cells.
Of note, although a screen of pancreatic cancer cell lines revealed that a
majority (15/22) of pancreatic cancer cell lines exhibited a reduced ability to
downregulate cyclin D1, a large minority (7/22) still demonstrated an intact response
to ER stress induction. This variability in response illustrates the heterogeneity
encountered in pancreatic cancer cells and the hindrance facing treatment of
pancreatic cancers with single agents.
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In conclusion, this dissertation provides evidence of an altered unfolded
protein response in pancreatic cancer cells that results in continued proliferation
under conditions that should induce ER stress. These findings demonstrate that
pancreatic cancer cells possess an adaptive mechanism that enables continued
proliferation in the presence of ER stress-inducing conditions.

FUTURE DIRECTIONS
What is the mechanism for global resistance to UPR activation in pancreatic
cancer cells?
My current study identified that a mechanism upstream of the UPR exists
that enables late activation of the PERK/eIF2α/ATF4/CHOP and IRE1α/XBP1s
arms of the UPR. However, further investigation of potential mechanisms for this
global resistance to UPR activation is required if a potential therapeutic target is to
be identified for further evaluation. Some suggested causes of this impaired UPR
activation include increased ER chaperone expression or autophagy. Increased ER
chaperone expression may provide increased protein load capacity that requires
increased protein entry into the secretory ER pathway in order to induce ER stress.
Autophagy may provide increased autophagosomal capacity for sequestering of
aggregated proteins away from the ER, thus limiting proteotoxic stress.
Determination of a causative factor for the increased tolerance for ER stress in
pancreatic cancer would provide a therapeutic target that could sensitize pancreatic
cancer cells to ER stress-mediated apoptosis. Additionally, more extensive study
of UPR activation after treatment with other ER stressors needs to be included to
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determine whether this global impairment of the UPR extends to ER stress
conditions beyond tunicamycin’s inhibition of N-linked glycosylation.

Other ER

stress conditions, such as hypoxia, have also been established as inducing
translational attenuation by the eIF2α arm of the UPR.

Additional studies are

required to examine whether the global impairment of the UPR in pancreatic cancer
cells extends to other types of ER stress.

How does the pancreatic tumor microenvironment influence ER stress
activation?
This study investigated the role of the UPR activation in pancreatic cancer
cells. However, the contribution of the tumor microenvironment was not directly
tested in this experiment.

We do not underestimate the importance of the

pancreatic tumor microenvironment, particularly given that our hypothesis assumes
a hypovascular tumor microenvironment imparts the need for adaptability to ER
stress. Pancreatic adenocarcinomas also contain extensive stroma that has been
shown to influence vascular supply to pancreatic cancer cells in mouse transgenic
models (134).

We can further examine the tumor microenvironment by stably

transfecting pancreatic cancer center lines with luciferase reporters for XBP1
splicing and ATF4 activation.
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Does persistent XBP1s activation in pancreatic cancer cells enable continued
tolerance to ER stress?
XBP1s has been demonstrated to play a critical role in tumor cell survival
during hypoxia.

XBP1-deficient cells displayed an increased susceptibility to

apoptosis during severe hypoxic stress and impaired tumor growth (104).
Additionally, XBP1 expression has been shown to be highly expressed in hypoxic
tumor regions (103). Our studies indicate that once activated, XBP1s is robustly
expressed for an extended duration in pancreatic cancer cells compared to a rapid
decline in non-tumorigenic cell lines.
compensatory

mechanism

for

I hypothesize that this response is a

deficient

eIF2α

phosphorylation.

Further

investigation of the importance of XBP1s in pancreatic cancer cell survival could be
achieved through knockdown of XBP1s.
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